

**UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)***(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.
CEDAR-44649Total Pages in this Submission
115**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**MODULATING ACTIVATION OF LYMPHOCYTES AND SCREENING POTENTIAL
IMMUNOMODULATING AGENTS BY TARGETING PITUITARY TUMOR TRANSFORMING GENE (PTTG)
EXPRESSION AND/OR
FUNCTION**

and invented by:

Rostyslav Stoika, Gregory A. Horwitz, Xun Zhang and Shlomo Melmed

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: 09/569,956

Which is a:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No.: 08/894,251

filed as a national stage application, under 35 U.S.C. § 371, of international application PCT/US97/21463, which claims the priority filing date of U.S. Provisional Patent Application Serial No. 60/031,338.

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 93 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications *(if applicable)*
 - c. ☒ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Microfiche Appendix *(if applicable)*
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings *(if drawings filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
CEDAR-44649

Total Pages in this Submission

115

Application Elements (Continued)

3. ☒ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
a. ☐ Formal b. ☒ Informal Number of Sheets 14
4. ☒ Oath or Declaration
a. ☐ Newly executed *(original or copy)* ☒ Unexecuted
b. ☐ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
c. ☐ With Power of Attorney ☐ Without Power of Attorney
d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference *(usable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied
under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.
6. ☐ Computer Program in Microfiche
7. ☐ Genetic Sequence Submission *(if applicable, all must be included)*
a. ☐ Paper Copy
b. ☐ Computer Readable Copy
c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers *(cover sheet & documents)*
9. ☐ 37 CFR 3.73(b) Statement *(when there is an assignee)*
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
☐ First Class ☒ Express Mail *(Specify Label No.):* EL 537830543 US

UTILITY PATENT APPLICATION TRANSMITTAL
(Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
CEDAR-44649

Total Pages in this Submission

115

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Small Entity Statement(s) - Specify Number of Statements Submitted: _____
17. ☐ Additional Enclosures (please identify below):


Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	53	- 20 =	33	x \$9.00	\$297.00
Indep. Claims	4	- 3 =	1	x \$40.00	\$40.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$355.00
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					\$692.00

- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☐ Credit any overpayment.
- ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: October 13, 2000


Signature

Nisan A. Steinberg, Ph.D.
Registration No. 40,345
Sidley & Austin
555 West Fifth Street
Los Angeles, California 90013-1010
Telephone: (213) 896-6665
Facsimile: (213) 896-6600

cc:

10-16-00

A

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): **Rostyslav Stoika, et al.**

Docket No.

CEDAR-44649

Serial No.

Filing Date

Examiner

Group Art Unit

10/13/00

Invention:

**MODULATING ACTIVATION OF LYMPHOCYTES AND SCREENING POTENTIAL
IMMUNOMODULATING AGENTS BY TARGETING PITUITARY TUMOR TRANSFORMING
GENE (PTTG) EXPRESSION AND/OR FUNCTION**

JC925 U.S. PTO
09/687911

10/13/00

I hereby certify that the following correspondence:

Utility Patent Application Transmittal

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under

37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231

October 13, 2000

(Date)

Ann Weiss

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

("Express Mail" Mailing Label Number)

Note: Each paper must have its own certificate of mailing.

APPLICATION

for

UNITED STATES LETTERS PATENT

on


MODULATING ACTIVATION OF LYMPHOCYTES AND SCREENING
POTENTIAL IMMUNOMODULATING AGENTS BY TARGETING PITUITARY
TUMOR TRANSFORMING GENE (PTTG) EXPRESSION AND/OR FUNCTION

by

Rostyslav Stoika
Gregory A. Horwitz
Xun Zhang
and
Shlomo Melmed

Sheets of Drawings: 14
Docket No.: CEDAR-44649

Sidley & Austin
555 West Fifth Street, Suite 4000
Los Angeles, California 90013

CERTIFICATE OF MAILING BY "EXPRESS MAIL"	
"EXPRESS MAIL" MAILING LABEL NUMBER	<u>EL537830543 US</u>
DATE OF DEPOSIT	<u>13 OCTOBER 2000</u>
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1-10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO BOX NEW PATENT APPLICATION, THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D. C. 20231.	
ANN WEISS	
(TYPED OR PRINTED NAME OR PERSON MAILING PAPER OR FEE)	
	
(SIGNATURE OF PERSON MAILING PAPER OR FEE)	

MODULATING ACTIVATION OF LYMPHOCYTES AND SCREENING POTENTIAL
IMMUNOMODULATING AGENTS BY TARGETING PITUITARY TUMOR
TRANSFORMING GENE (PTTG) EXPRESSION AND/OR FUNCTION

The U.S. Government has a paid-up license in this invention and the right
5 in limited circumstances to require the patent owner to license others on reasonable terms as
provided for by the terms of Contract CA75979, awarded by the National Cancer Institute of the
National Institutes of Health.

This application is a continuation-in-part of U.S. Serial No.09/569,956, filed on May 12,
2000, which is a continuation-in-part of U.S. Serial No. 08/894,251, filed on July 23, 1999, as
10 a national stage application, under 35 U.S.C. § 371, of international application
PCT/US97/21463, filed November 21, 1997, which claims the priority of the filing date of U.S.
Provisional Application Serial No. 60/031,338, filed November 21, 1996.

BACKGROUND OF THE INVENTION

Throughout the application various publications are referenced in parentheses. The
15 disclosures of these publications in their entireties are hereby incorporated by reference in the
application in order to more fully describe the state of the art to which this invention pertains.

1. Field of the Invention

The present invention relates to a method of modulating human lymphocyte activation and
the use thereof in an in vitro method of screening potential immunosuppressive agents.

20 2. Related Art

Pituitary Tumor Transforming Gene (*PTTG*) is highly expressed in pituitary tumors and
neoplasms from the hematopoietic system and colon. (Zhang, X. *et al.*, *Structure, expression,
and function of human pituitary tumor-transforming gene (PTTG)*, Mol. Endocrinol. 13:156-66
[1999a]; Zhang, X. *et al.*, *Pituitary tumor transforming gene (PTTG) expression in pituitary
25 adenomas*, J. Clin. Endocrinol. Metab. 84:761-67 [1999b]; Heaney, A.P. *et al.*, *Pituitary tumor
transforming gene in colorectal tumors*, Lancet 355:712-15[2000]; Dominguez, A. *et al.*, *hpttg*,

a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG, Oncogene 17:2187-93 [1998]; Saez, C. *et al.*, *hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias*, Oncogene 18:5473-6 [1999]).

- 5 Levels of *PTTG* expression positively correlate with pituitary tumor invasiveness (Zhang, X. *et al.* [1999b]) and are induced by estrogen. (Heaney, A.P. *et al.*, *Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis*, Nat. Med. 5:1317-21 [1999]). In tumor cells, *PTTG* mRNA and protein expressions are cell cycle-dependent and peak at G2/M phase. (Run, Y. *et al.*, *Pituitary*
- 10 *Tumor Transforming Gene (PTTG) Regulates Placental JEG-3 Cell Division and Survival: Evidence from Live Cell Imaging*, Mol. Endocrinol. 14:1137-1146 [2000]). The mechanism of *PTTG* action is not very clear. *PTTG* upregulates basic fibroblast growth factor secretion (Zhang, X. *et al.* [1999a]), and transactivates DNA transcription (Dominguez, A. *et al.* [1998]; Wang, Z. *et al.*, *Pituitary tumor transforming gene (PTTG) transactivating and transforming*
- 15 *activity*, J. Biol. Chem. 275:7459-61[2000]).

- PTTG* encodes a securin protein the expression of which causes cell transformation, induces the production of basic fibroblast growth factor (bFGF), is regulated in vitro and in vivo by estrogen, and inhibits chromatid separation. (Pei, L., and Melmed S., *Isolation and characterization of a pituitary tumor transforming gene*, Mol. Endocrinol. 11:433-441 [1997];
- 20 Zhang, X., *et al.*, *Structure, expression, and function of human pituitary tumor-transforming gene (PTTG)*, Mol. Endocrinol. 13:156-166 [1999a]; Heaney, A.P., *et al.*, *Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis*, Nature Med. 5:1317-1321 [1999]; Zou, H., *et al.*, *Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis*,
- 25 Science 285:418-422 [1999]). By dysregulating chromatid separation, *PTTG* overexpression also leads to aneuploidy, i.e., cells having one or a few chromosomes above or below the normal chromosome number (Zou *et al.* [1999]).

- At the end of metaphase, securin is degraded by an anaphase-promoting complex, releasing tonic inhibition of separin, which in turn mediates degradation of cohesins, the proteins
- 30 that hold sister chromatids together. Overexpression of a nondegradable *PTTG* disrupts sister

chromatid separation (Zou *et al.* [1999]) and overexpression of *PTTG* causes apoptosis and inhibits mitoses (Run, Y. *et al.* [2000]). The securin function of *PTTG* suggests that *PTTG* may also be expressed in normal proliferating cells. In adult animals and humans, *PTTG* mRNA is most abundant in testis (Zhang, X. *et al.* [1999a]); Wang, Z. *et al.* [2000]), an organ containing

5 rapidly proliferating gametes.

The recent discovery of a human *PTTG* gene 2, which shares high sequence homology with human *PTTG1*, implying the existence of a *PTTG* gene family. (Prezant, T.R., *et al.*, *An intronless homolog of human proto-oncogene hPTTG is expressed in pituitary tumors: evidence for hPTTG family*, J. Clin. Endocrinol. Metab. 84:1149-1152 [1999]). Murine *PTTG* shares

10 66% nucleotide base sequence homology with human *PTTG1* and also exhibits transforming ability. (Wang, Z. and Melmed, S., *Characterization of the murine pituitary tumor transforming gene (PTTG) and its promoter*, Endocrinology [In Press; 2000]). A proline-rich region was identified near the protein C-terminus that is critical for *PTTG1*'s transforming activity. (Zhang, X., *et al.* [1999a]), as demonstrated by the inhibitory effect on in vitro transformation, in vivo

15 tumorigenesis, and transactivation, when point mutations were introduced into the proline-rich region. Proline-rich domains may function as SH3 binding sites to mediate signal transduction of protein-tyrosine kinase. (Pawson, T., *Protein modules and signaling networks*, Nature 373:573-580 [1995]; Kuriyan, J., and Cowburn, D., *Modular peptide recognition domains in eukaryotic signaling*, Annu. Rev. Biophys. Biomol. Struct. 26:259-288 [1997]).

20 T-lymphocyte ("T-cells") are a class of lymphocytes, so called because they are derived from the thymus and have been through thymic processing. T-lymphocyte cells are an important component of the immune system. Upon confronting an antigen, activated T-cells enter rapid proliferation from a quiescent state. Activated T-cells contribute significantly to graft rejection and to asthmatic, allergic and auto-immune conditions or diseases. (See, e.g., Yi, S. *et al.*,

25 *CD8+ T cells are capable of rejecting pancreatic islet xenografts*, Transplantation 70(6):896-906 [2000]; Han, W.R. *et al.*, *Prolonged allograft survival in anti-CD4 antibody transgenic mice: lack of residual helper T cells compared with other CD4-deficient mice*, Transplantation 70(1):168-74 [2000]; Uchida, T. *et al.*, *Roles of CD4+ and CD8+ T cells in discordant skin xenograft rejection*, Transplantation 68(11):1721-27 [1999]; Krieger, N.R. *et al.*, *Rat pancreatic islet and skin xenograft survival in CD4 and CD8 knockout mice*, J. Autoimmun. 10(3):309-15

30

- [1997]; Simeonovic, C.J. *et al.*, *Differences in the contribution of CD4+ T cells to proislet and islet allograft rejection correlate with constitutive class II MHC alloantigen expression*, Cell Transplant 5(5):525-41 [1996]; Kenyon, N.J. *et al.*, *Enhanced cytokine generation by peripheral blood mononuclear cells in allergic and asthma subjects*, Ann. Allergy. Asthma. Immunol. 85(2):115-20 [2000]; Wang H.B. *et al.*, *Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis*, Int. Immunol. 12(10):1381-1388 [2000]; Arnett, F.C., *Genetic studies of human lupus in families*, Int. Rev. Immunol. 19(4-5):297-317 [2000]; Nickoloff, B.J. *et al.*, *Is psoriasis a T-cell disease?*, Exp. Dermatol. 9(5):359-75 [2000]; Griffin, J.M. *et al.*, *CD4(+) T-Cell Activation and Induction of Autoimmune Hepatitis following Trichloroethylene Treatment in MRL+/+ Mice*, Toxicol. Sci. 57(2):345-352 [2000]; George, J. *et al.*, *Adoptive Transfer of beta(2)-Glycoprotein I-Reactive Lymphocytes Enhances Early Atherosclerosis in LDL Receptor-Deficient Mice.*, Circulation 102(15):1822-1827 [2000]; Karandikar, N.J. *et al.*, *CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis*, J Neuroimmunol. 109(2):173-80 [2000]; Nakajima A. *et al.*, *Involvement of CD70-CD27 interactions in the induction of experimental autoimmune encephalomyelitis*, J. Neuroimmunol. 109(2):188-96[2000]; Grom, A.A., and Hirsch R., *T-cell and T-cell receptor abnormalities in the immunopathogenesis of juvenile rheumatoid arthritis*, Curr. Opin. Rheumatol. 12(5):420-4 [2000]].
- Consequently, immunosuppressive agents (i.e., chemotherapeutic agents that have the effect of suppressing the immune system), such as cyclosporin, rapamycin, or tacrolimus, are typically used therapeutically to enhance graft survival or to inhibit severe allergic or autoimmune responses mediated by the effects of interleukins and other cytokines. Most often these immunosuppressive agents reduce the absolute number of white blood cells in the bloodstream and they may act by any of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of suppressor T-cell populations or by inhibiting the activation of helper cells. Many immunosuppressive agents have broad toxic effects that make their use in some patients unpleasant and/or hazardous. Therefore, there is a need to search for new less toxic immunosuppressive agents.

Some screening methods for immunosuppressive agents have been developed. For example, Weiss *et al.* (*Screening assay for the identification of novel immunosuppressives using cultured T cells*, U.S. Patent No. 5,474,897) taught a method for identifying compounds capable of inducing immunosuppression by inhibiting the CD28 signal transduction pathway in T-cells.

5 But the multiple pathway redundancies present in immune cells limit the usefulness of a method devoted to only the CD28 pathway.

Mochimasa *et al.* (*Method for screening immunosuppressive substance*, JP7322891A2 and JP7322892A2; *Yeast variant highly sensitive to immunosuppressive agents and its application*, JP9173053A2) taught screening methods employing calcium-sensitive yeast cells.

10 However, yeast cells are a relatively poor model for mammalian T-lymphocyte cells.

Thus, the need remains for a reliable method for screening potential immunosuppressive agents.

There also remains a need for additional treatment methods of immunosuppression are especially desirable that are more targeted and narrowly acting than the pharmacological methods

15 currently available.

These and other benefits are provided by the present invention as described herein.

SUMMARY OF THE INVENTION

The present invention relates to compositions useful for inhibiting neoplastic cellular proliferation and/or transformation, which compositions are also useful for modulating, i.e.,
20 inhibiting or inducing, the activation of normal mammalian T-lymphocyte cells. These compositions include PTTG-specific antisense oligonucleotides, which antisense oligonucleotides can be selected to target any PTTG-specific genomic or mRNA sequence (including splice variants) so as to prevent expression of functional PTTG protein. Included are compositions comprising a PTTG carboxy-terminal peptide or comprising a chimeric or fusion protein that
25 contains a first PTTG carboxy-terminal peptide segment and a second cellular uptake-enhancing peptide segment. The invention also relates to compositions comprising a PTTG carboxy-terminal-related polynucleotide, for example, a polynucleotide encoding a PTTG-C peptide or antisense PTTG-C-related oligonucleotides. Also included in the invention are compositions comprising expression vectors containing the PTTG-C-related polynucleotides, including nucleic

acids encoding PTTG-C peptides. The inventive PTTG-C peptides and inventive PTTG-C-related polynucleotides are useful in the manufacture of pharmaceutical compositions, medicaments or medicants for inhibiting neoplastic cellular proliferation and/or transformation or for inhibiting the activation of mammalian T-lymphocytes, which contain the inventive *PTTG*-specific antisense oligonucleotides, PTTG-C peptides and PTTG-C-related polynucleotides.

In accordance with the present invention, there are also provided PTTG carboxy-terminal (PTTG-C) peptides and PTTG-C-related polynucleotides, which can also be isolated from other cellular components. The inventive PTTG-C peptides are useful in bioassays, as immunogens for producing anti-PTTG antibodies, or in therapeutic compositions containing such peptides and/or antibodies. Also provided are transgenic non-human mammals that comprise mammalian cells that comprise embodiments of the inventive PTTG-C-related polynucleotides and express the inventive PTTG-C peptides.

The compositions and methods are useful for inhibiting neoplastic and non-neoplastic proliferation of mammalian T-lymphocyte cells, including activated normal lymphocytes and transformed lymphocytes. The inventive compositions and methods are useful in the prevention or inhibition of xenograft or allograft rejection, and in the treatment of allergic, asthmatic and/or autoimmune conditions, such as systemic lupus erythematosus (SLE), autoimmune myasthenia gravis, rheumatoid arthritis, autoimmune encephalomyelitis, psoriasis, atherosclerosis, and other autoimmune diseases. The inventive methods and compositions are also useful in the treatment of T-cell neoplasias, such as leukemia, or any hematologic or lymphopoietic neoplasm, for example, Hodgkins disease.

In particular, the present invention is also related to a method of inhibiting the activation of a mammalian T-lymphocyte cell, including human cells, whether *in vitro* or *in vivo*. The method involves inhibiting *PTTG* expression and/or endogenous PTTG function in the T-lymphocyte cell, whereby activation of the T-lymphocyte cell is inhibited. The method can be practiced by delivering to the T-lymphocyte cell a *PTTG*-specific antisense oligonucleotide, which antisense oligonucleotide can be selected to target any *PTTG*-specific genomic or mRNA sequence (including splice variants) so as to prevent expression of functional PTTG protein. Alternatively, the method can be practiced by interfering with SH3-mediated signal transduction by blocking specific binding to SH3-binding sites on endogenous PTTG protein molecules in T-

lymphocytes. Alternatively, the method can be practiced by inhibiting *PTTG* expression by targeting with antisense oligonucleotides directed to any of several regulatory regions that have been identified in the *PTTG* promoter such as SSCA, 8182, cyclic-AMP responsive element, an estrogen responsive element, insulin response element, SP1, and GC Box, as well as others.

5 Alternatively, embodiments of the method of inhibiting the activation of a mammalian T-lymphocyte involve inhibition of *PTTG* expression and/or endogenous *PTTG* function in the T-lymphocyte cell by delivering to the mammalian T-lymphocyte cell a composition comprising a *PTTG* carboxy-terminal-related polynucleotide, or comprising a *PTTG* carboxy terminal peptide (*PTTG*-C), or a biologically functional fragment thereof. The polynucleotide or peptide is
10 complexed with a cellular uptake-enhancing agent, in an amount and under conditions sufficient to allow the polynucleotide or peptide to enter the cell, whereby activation of the lymphocyte cell is inhibited.

 The present method of modulating the activation of a mammalian T-lymphocyte encompasses embodiments for enhancing or inducing the activation of T-lymphocytes, which
15 embodiments involve delivering to the cells compositions that enhance *PTTG* expression and/or *PTTG* protein function, including estrogens and/or lymphocytic mitogens. Delivering compositions to the T-lymphocyte cells that include expression vectors comprising *PTTG*-encoding polynucleotides that, within the cells, increase the expression of functional *PTTG* protein to above endogenous levels are alternatively contemplated within the present invention.

20 The present invention also relates to an in vitro method for screening substances for new immunosuppressive agents. Substances include pure or isolated compounds and mixtures of compounds, for example extracts from biological samples, such as plant, animal, bacterial, protist, or fungal extracts. The method involves culturing lymphocytes; exposing the cultured T-lymphocytes to a potential immunosuppressive agent in the presence of a known
25 lymphocyte activator; and detecting a change in the expression level of *PTTG* in the lymphocytes compared to control lymphocytes not exposed to the potential immunosuppressive agent, downregulation of *PTTG* expression being indicative of an immunosuppressive capacity possessed by the potential immunosuppressive agent.

 Similarly, the present invention relates to an in vitro method for screening substances
30 for new immunoenhancing agents that enhance the activation of T-lymphocytes. The method

involves culturing lymphocytes; exposing the cultured T-lymphocytes to a potential immunoenhancing agent; and detecting a change in the expression level of PTTG in the lymphocytes compared to control lymphocytes not exposed to the potential immunoenhancing agent, upregulation of PTTG expression being indicative of an immunoenhancing capacity

5 possessed by the potential immunosuppressive agent.

The present invention also relates to a method of inhibiting neoplastic cellular proliferation and/or transformation of any mammalian cells, including human cells and mammalian T-lymphocytes, whether in vitro or in vivo. The inventive method relies on the discovery that the native carboxy-terminal portion of the pituitary tumor transforming gene protein (PTTG) is

10 critical to PTTG protein function and that, surprisingly, pituitary tumor transforming gene carboxy-terminal peptide (PTTG-C) molecules have the ability to downregulate pituitary tumor transforming gene (*PTTG*) expression and/or PTTG function in a dominant negative manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG carboxy-terminal-related polynucleotides to mammalian cells to inhibit the endogenous expression

15 and function of *PTTG*. Other embodiments are directed to peptide-based treatments that deliver PTTG-C peptides to the cells, which inhibit endogenous PTTG expression and/or PTTG function.

Useful gene-based embodiments of the method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian cells involve delivering to the cell a composition

20 comprising a PTTG-C-related polynucleotide that includes a base sequence that defines a PTTG carboxy-terminal peptide-encoding sequence, or defines a degenerate sequence, or defines a sequence complementary to either of these. In accordance with the method, the PTTG carboxy-terminal-related polynucleotide, preferably complexed with a cellular uptake-enhancing agent, is delivered in an amount and under conditions sufficient to enter the cell, thereby inhibiting

25 neoplastic cellular proliferation and/or transformation of the cell.

Alternatively, useful peptide-based embodiments of the method of inhibiting neoplastic cellular proliferation and/or transformation of a mammalian cell involve delivering to a mammalian cell a composition comprising a PTTG carboxy-terminal peptide (PTTG-C), or a biologically functional fragment thereof, preferably complexed with a cellular uptake-enhancing agent, in an

30 amount and under conditions sufficient to enter the cell, thereby inhibiting neoplastic cellular

proliferation and/or transformation.

Because, PTTG protein further mediates the expression of bFGF, an important angiogenesis activator, the inventive method of inhibiting neoplastic cellular proliferation and/or transformation, practiced in vivo, also encompasses a method of inhibiting tumor angiogenesis.

- 5 Angiogenesis activators, including bFGF and VEGF, are expressed and secreted by most human carcinoma cells. (Plate, K. H. *et al.*, Nature 359:845-48 [1992]; Schultz-Hector, S. and Haghayegh, S., Cancer Res. 53:1444-49 [1993]; Yamanaka, Y. *et al.*, Cancer Res. 53:5289-96 [1993]; Buensing, S. *et al.*, Anticancer Res. 15:2331-34 [1995]). The discovery, described herein, that the inventive PTTG-C peptides dramatically reduce bFGF production by cancer cells
10 (e.g., HeLa), shows that in accordance with the inventive method, the inventive PTTG-C peptides can impair new blood vessel growth, which is essential for tumor growth. Thus, the method of inhibiting tumor angiogenesis further inhibits neoplastic cellular proliferation, in vivo.

- Also provided are antibodies that are specifically immunoreactive with PTTG proteins, or more particularly, with PTTG-C peptides. The inventive antibodies specifically bind to PTTG-C
15 peptides. These anti-PTTG-C-specific antibodies are useful in assays to determine levels of PTTG proteins or PTTG-C peptides present in a given sample, e.g., tissue samples, biological fluids, Western blots, and the like. The antibodies can also be used to purify PTTG proteins or PTTG-C peptides from crude cell extracts and the like. Moreover, these antibodies are considered therapeutically useful to counteract or supplement the biological effect of PTTG
20 proteins in vivo. Thus, the antibodies are useful in inhibiting the activation of mammalian T-lymphocytes.

Useful kits are also provided for facilitating the practice of the inventive methods.

- The present invention is further described by related applications U.S. Serial No.09/569,956, filed on May 12, 2000; U.S. Serial No. 08/894,251, filed July 23, 1999; international application
25 PCT/US97/21463, filed November 21, 1997; and U.S. provisional application 60/031,338, filed November 21, 1996, the disclosures all of which are incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 illustrates transcriptional activation in transfected NIH 3T3 cells, as mediated by pGAL4, pGAL4-VP16, pGAL4-wtPTTG, or pGAL4-mutPTTG 48 hours after transfection. Cell

lysate proteins were assayed for luciferase and β -gal expression. pGAL4 was used as a negative control and pGAL4-VP16 as a positive control.

Figure 2 shows PTTG-C and PTTG-Cpm expression in transfected tumor cells. Figure 2A illustrates expression construct which express a C-terminal peptide of human PTTG protein (PTTGC), corresponding to amino acid residues 147-202 of SEQ. ID. NO.:4 (i.e., SEQ. ID. NO.:9), under the control of the CMV promoter (black bar). PXXP represents the proline-rich region(s) of the PTTG-C. A mutant expression vector (PTTG-Cpm), contained point mutations P163A, S165Q, P166L, P170L, P172A, and P173L. Figure 2B includes representative 1% agarose gels of RT-PCR products of HeLa (top panel), T-47D (middle panel), and MCF-7 cells (bottom panel), showing PTTG-C and PTTG-Cpm expression. Products from reverse transcription carried out in the presence (+) or absence (-) of RT were used as template in PCR reactions. Figure 2C shows a representative sequencing gel from RT-PCR followed by direct sequencing analysis showing PTTG-C and PTTG-Cpm expression in respective transfectants. Arrows point to nucleotide changes.

Figure 3 shows colony formation of HeLa (top row), T-47D (middle row), and MCF-7 (bottom row) cells transfected with PTTG-C or PTTG-Cpm expression vectors on soft agar. "Vector" (left column) shows cells transfected with vector pCI-neo alone; "PTTG-C" (middle column) shows cells transfected with vector pCI-neo containing PTTG C-terminal encoding cDNA; "PTTG-Cpm" (right column) shows cells transfected with vector pCI-neo containing mutant PTTG C-terminal cDNA (P163A, S165Q, P166L, P170L, P172A, and P173L).

Figure 4 shows suppression of bFGF secretion by HeLa cells expressing PTTG-C peptide. The concentration of bFGF in conditioned medium derived from transfectants cultured for 72 h as measure by ELISA. "Vector" (two left-most bars) indicates medium conditioned by cells transfected with vector pCI-neo alone; "PTTG-C" (three middle bars) indicates medium conditioned by cells transfected with vector pCI-neo containing wtPTTG-C-terminal encoding cDNA; "PTTG-Cpm" (three right-most bars) indicates medium conditioned by transfected with vector pCI-neo containing mutant PTTG C-terminal encoding cDNA (P163A, S165Q, P166L, P170L, P172A, and P173L).

Figure 5 shows *PTTG* mRNA expression in normal adult human T-cells treated with mitogen anti-CD3 antibody. T-cells were isolated and stimulated with anti-CD3 antibody for 72 hours.

PTTG mRNA PTTG was measured with northern blotting and percentage of cells in S or G2/M phase was determined by FACS.

Figure 6 shows *PTTG* mRNA expression in normal adult human T-cells treated with mitogen phytohemagglutinin (PHA). T-cells were isolated and stimulated with increasing concentrations of PHA for 72 hours. *PTTG* mRNA was measured with northern blotting and percentage of cells in S or G2/M phase was determined by FACS.

Figure 7 shows *IL-2* mRNA expression in normal adult human T cells treated with mitogen CD3 antibody. T-cells were isolated and stimulated with anti-CD3 antibody for 72 hours. *IL-2* mRNA PTTG was measured with northern blotting and percentage of cells in S or G2/M phase was determined by FACS.

Figure 8 shows cyclophilin mRNA expression in normal adult human T cells treated with mitogen CD3 antibody. T cells were isolated and stimulated with anti-CD3 antibody for 48 hours. Cyclophilin mRNA PTTG was measured with northern blotting.

Figure 9 demonstrates *PTTG* mRNA expression and hydrocortisone. PHA (5 μ g/mL)-stimulated normal adult human T cells were treated with hydrocortisone for 72 hours. *PTTG* mRNA was measured with northern blotting and percentage of cells in S or G2/M phase was determined by FACS.

Figure 10 shows *PTTG* mRNA expression and cyclosporin. PHA (5 μ g/mL)-stimulated normal adult human T cells were treated with cyclosporin for 72 h. *PTTG* mRNA was measured with northern blotting and percentage of cells in S or G2/M phase was determined by FACS.

Figure 11 illustrates *PTTG* mRNA expression in leukemia cells. *PTTG* mRNA values and cell cycle of cycling human leukemia HL-60 (1), Jurkat T cells (2), resting (3), PHA (5 μ g/mL)-stimulated, (4) anti-CD3-stimulated, and (5) normal adult human T cells were determined.

Figure 12 shows *PTTG* mRNA expression and cell cycle in T cells. T cells were treated with the following conditions and *PTTG* mRNA and percentage of S phase were compared. (1) resting cells; (2) PHA (5 μ g/mL)-stimulated; (3) anti-CD3-stimulated; (4) anti-CD3 + hydrocortisone (100 nM); (5) anti-CD3 + cyclosporine A (1 μ g/mL); (6) anti-CD3 + aphidicolin (1 μ g/mL); (7) anti-CD3 + nocodazole (500 ng/mL); (8) anti-CD3 + TGF- β 1 (10 ng/mL).

Figure 13 shows *PTTG* mRNA expression in human Jurkat T cell leukemia line. Jurkat T cells were treated as described below. (1) cells kept for 48 h in 1% FBS-supplemented culture

medium; (2) cells after medium change for fresh 1% FBS-supplemented; (3) cells after medium change for 10% FBS-supplemented; (4) phytohemagglutinin (PHA; 1 μ g/mL) + phorbol-12-meristate-13-acetate (PMA; 50 ng/mL) in 1% FBS; (5) (PHA + PMA) + cyclosporine A (1 μ g/mL); (6) (PHA + PMA) + TGF- β 1 (10 ng/mL).

5 DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION

The present invention relates to a method of inhibiting the activation of mammalian T-lymphocyte cells, including human T-lymphocyte cells. Any T-lymphocyte variety is included which is derived from stem cells of the lymphoid series. The T-lymphocyte varieties include those commonly known in the art as helper (e.g., CD4 helper cells), suppressor (e.g., CD8 suppressor
10 cells), and cytotoxic T-cells, as well as naive or memory T-cells, whether resting, activated, or proliferating (e.g., T-lymphoblasts). They include T-lymphocytes expressing $\alpha\beta$ receptor or $\gamma\delta$ receptor, as well as CD3, CD28, CD4, and/or CD8. Activated T-lymphocytes are typically identified, *inter alia*, by enhanced expression of CTLA4 and/or CD40 ligand. They also express MHC class II and other antigenic markers, not expressed by non-activated cells.
15 Morphologically, they are known to the skilled artisan to be larger than non-activated T-cells. Other physiological and/or electrophysiological characteristics of activated T-lymphocytes are also known in the art (e.g., altered calcium ion flux).

The present invention also relates to a method of inhibiting *PTTG*-mediated neoplastic cellular proliferation and/or transformation of a mammalian cell, including T-lymphocytes.

20 For the purposes of the inventive methods, the mammalian cell is a cell of human or non-human origin, for example, a human lymphocyte cell or a non-human lymphocyte, or other cell type, originating from, or in, any mammalian animal, e.g., a non-human primate, rat, mouse, rabbit, guinea pig, hamster, bovine, porcine, ovine, equine, canine, feline, pachyderm, and the like. The mammalian cell can be situated *in vivo*, i.e., within a mammalian animal subject or human
25 subject, or *in vitro*, i.e., the cell can be a cultured cell.

For the purposes of the invention, "neoplastic cellular proliferation" includes neoplastic (malignant or benign), hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation in a mammalian subject or cell culture. Hyperplastic cellular growth or

proliferation includes abnormal multiplication or increase in the numbers of normal cells in a normal arrangement in a tissue, for example, as is common in benign prostatic hyperplasia. Cytologically dysplastic and/or premalignant cellular growth or proliferation include increases in cellular numbers of karyotypically abnormal but non-malignant cells within a tissue. Examples
5 include some benign prostatic hyperplasias/dysplasia and cervical hyperplasias/dysplasias.

Neoplastic cellular growth and/or proliferation, i.e., growth of abnormally organized tissue, includes malignant and non-malignant neoplasms. Malignant neoplasms include primary, recurrent, and/or metastatic cancerous tumors originating in any tissues, for example, carcinomas, sarcomas, lymphomas, mesotheliomas, melanomas, gliomas, nephroblastomas,
10 glioblastomas, oligodendrogliomas, astrocytomas, ependymomas, primitive neuroectodermal tumors, atypical meningiomas, malignant meningiomas, or neuroblastomas, originating in the pituitary, hypothalamus, lung, kidney, adrenal, ureter, bladder, urethra, breast, prostate, testis, skull, brain, spine, thorax, peritoneum, ovary, uterus, stomach, liver, bowel, colon, rectum, bone, lymphatic system, skin, or in any other organ or tissue of the subject.

15 In accordance with gene-based embodiments of the method of inhibiting neoplastic cellular proliferation and/or transformation, an inventive composition is delivered to the cell, which composition comprises a PTTG carboxy-terminal-related polynucleotide. A "PTTG carboxy-terminal-related" polynucleotide is a polynucleotide having a contiguous sequence of bases (e.g., adenine [A], thymine [T], uracil [U], guanine [G], and/or cytosine [C]) defining a sequence
20 specific to the 3' coding region of *PTTG*. The 3' -end or terminal extends from approximately the mid-point of a cDNA coding sequence encoding a native PTTG to its end at a stop codon.

The PTTG carboxy-terminal-related polynucleotide can be a sequence encoding a carboxy-terminal portion of a mammalian PTTG protein (i.e., a PTTG-C peptide), as described more fully below, or encoding a PTTG-specific fragment thereof, or a degenerate coding sequence, or a
25 sequence complementary to any of these.

In some preferred embodiments, the inventive composition includes a nucleic acid construct, such as a plasmid or viral expression vector, which comprises the polynucleotide in a sense or antisense orientation, and from which *PTTG*-specific mRNA transcript can be expressed in the cell. In a preferred embodiment, the nucleic acid construct contains a polynucleotide encoding
30 a mammalian PTTG carboxy-terminal (PTTG-C) peptide, which can be any PTTG-C peptide or

functional fragment thereof as described herein. The composition can also contain one or more helper plasmids or viruses, if appropriate. The plasmid or viral expression vector is a nucleic acid construct that includes a promoter region operatively linked to the polynucleotide in a transcriptional unit.

5 As used herein, a promoter region refers to a segment of DNA that controls transcription of a DNA to which it is operatively linked. The promoter region includes specific sequences that are sufficient for RNA polymerase recognition, binding and transcription initiation. In addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of RNA polymerase. These sequences may be *cis* acting or may be responsive
10 to *trans* acting factors. Promoters, depending upon the nature of the regulation, may be constitutive or regulated. Exemplary promoters contemplated for use in the practice of the present invention include the SV40 early promoter, the cytomegalovirus (CMV) promoter, the mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, and the like.

15 As used herein, "expression" refers to the process by which polynucleic acids are transcribed into mRNA and translated into peptides, polypeptides, or proteins. If the polynucleic acid is derived from genomic DNA, expression may, if an appropriate eukaryotic host cell or organism is selected, include splicing of the mRNA.

As used herein, the term "operatively linked" refers to the functional relationship of DNA with
20 regulatory and effector nucleotide sequences, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences. For example, operative linkage of DNA to a promoter refers to the physical and functional relationship between the DNA and the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA. Thus, "operatively linked" means
25 that, within a transcriptional unit, the promoter sequence, is located upstream (i.e., 5' in relation thereto) from the coding sequence and the coding sequence, is 3' to the promoter, or alternatively is in a sequence of genes or open reading frames 3' to the promoter and expression is coordinately regulated thereby. Both the promoter and coding sequences are oriented in a 5' to 3' manner, such that transcription can take place in vitro in the presence of all essential enzymes,
30 transcription factors, co-factors, activators, and reactants, under favorable physical conditions,

e.g., suitable pH and temperature. This does not mean that, in any particular cell, conditions will favor transcription. For example, transcription from a tissue-specific promoter is generally not favored in heterologous cell types from different tissues.

The term "nucleic acid" encompasses ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), which DNA can be complementary DNA (cDNA) or genomic DNA, e.g. a gene encoding a PTTG protein. "Polynucleotides" encompass nucleic acids containing a "backbone" formed by phosphodiester linkages between ribosyl or deoxyribosyl moieties. Polynucleotides also include nucleic acid analogs, for example polynucleotides having alternative linkages as known in the art. Examples include phosphorothioate linkages (e.g., phosphorothioate oligodeoxynucleotides; S-oligonucleotides), mixed phosphorothioate and phosphodiester linkages (e.g., S-O-oligodeoxynucleotides and phosphodiester/phosphorothioate 2'-O-methyl-oligoribonucleotides; Zhou, W. *et al.*, *Mixed backbone oligonucleotides as second-generation antisense agents with reduced phosphthioate-related side effects*, Bioorg. Med. Chem. Lett. 8(22):3269-74 [1998]), methylphosphonate-phosphodiester modifications (MP-O-oligonucleotides; Zhao, Q. *et al.*, *Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides*, Antisense Res. Dev. 3(1):53-66 [1993]), or morpholino oligonucleotides (e.g., Schmajuk, G. *et al.*, *Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake*, J. Biol. Chem. 274(31):21783-89 [1999]).

Also included among useful polynucleotides are nucleic acid analogs having a pseudopeptide or polyamide backbone comprising N-(2-aminoethyl)glycine moieties, i.e., peptide nucleic acids (PNA). (E.g., Nielsen, P.E., *Peptide nucleic acids: on the road to new gene therapeutic drugs*, Pharmacol. Toxicol. 86(1):3-7 [2000]; Soomets, U. *et al.*, *Antisense properties of peptide nucleic acids*, Front. Biosci. 4:D782-86 [1999]; Tyler, B.M. *et al.*, *Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression*, Proc. Natl. Acad. Sci. USA 96(12):7053-58 [1999]).

Polynucleotides include sense or antisense polynucleotides. "Polynucleotides" also encompasses "oligonucleotides".

A polynucleotide sequence complementary to a PTTG-specific polynucleotide sequence, as used herein, is one binding specifically with a PTTG-specific nucleotide base sequence. The

phrase “binding specifically” encompasses the ability of a polynucleotide sequence to recognize a complementary base sequence and to form double-helical segments therewith via the formation of hydrogen bonds between the complementary base pairs. Thus, a complementary sequence includes, for example, an antisense sequence with respect to a sense sequence or coding sequence.

5 In some embodiments of the PTTG-C-related polynucleotide, the polynucleotide is in a sense orientation within the transcriptional unit, such that mRNA transcript can be produced, which when translated results in a translation product, such as a PTTG protein or a PTTG carboxy-terminal peptide (PTTG-C). In other embodiments, the PTTG-C-related polynucleotide is in an antisense orientation such that transcription results in a transcript complementary to and
10 hybridizable with a naturally-occurring sense *PTTG* mRNA molecule under physiological conditions, inhibiting or blocking translation therefrom. Thus, antisense oligonucleotides inactivate target mRNA sequences by either binding thereto and inducing degradation of the mRNA by, for example, RNase I digestion, or inhibiting translation of mRNA target sequence by interfering with the binding of translation-regulating factors or ribosomes, or by inclusion of other
15 chemical structures, such as ribozyme sequences or reactive chemical groups which either degrade or chemically modify the target mRNA. For example, an antisense oligonucleotide targeted to a PTTG carboxy-terminal-related polynucleotide segment of mRNA or genomic DNA is effective in inhibiting expression of *PTTG*.

Gene-based therapy strategies employing antisense oligonucleotides are well known in the art.
20 (E.g., Rait, A. et al., *3'-End conjugates of minimally phosphorothioate-protected oligonucleotides with 1-O-hexadecylglycerol: synthesis and anti-ras activity in radiation-resistant cells*, Bioconjug Chem., 11(2):153-60 [2000]; Stenton, G. R. et al., *Aerosolized syk antisense suppresses syk expression, mediator release from macrophages, and pulmonary inflammation*, J. Immunol., 164(7):3790-7 [2000]; Suzuki, J. et al., *Antisense Bcl-x oligonucleotide induces apoptosis and prevents arterial neointimal formation in murine cardiac allografts*, Cardiovas. Res., 45(3):783-7 [2000]; Kim, J. W. et al., *Antisense oligodeoxynucleotide of glyceraldehyde-3-phosphate dehydrogenase gene inhibits cell proliferation and induces apoptosis in human cervical carcinoma cell line*, Antisense Nucleic
25 Acid Drug Dev., 9(6):507-13 [1999]; Han, D. C. et al., *Therapy with antisense TGF- β 1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice*, Am. J.
30

- Physiol. Renal Physiol., 278(4):F628-F634 [2000]; Scala, S. et al., *Adenovirus-mediated suppression of HMGI (Y) protein synthesis as potential therapy of human malignant neoplasias*, Proc. Natl. Acad. Sci. USA., 97(8):4256-4261 [2000]; Arteaga, C. L., et al., *Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice*, 5 Cancer Res., 56(5):1098-1103 [1996]; Muller, M. et al., *Antisense phosphorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor I receptor in ovarian cancer cells*, Int. J. Cancer, 77(4):567-71 [1998]; Engelhard, H. H., *Antisense Oligodeoxynucleotide Technology: Potential Use for the Treatment of Malignant Brain Tumors*, Cancer Control, 5(2):163-170 [1998]; Alvarez-Salas, L. M. et al., *Growth inhibition of cervical tumor cells by antisense oligodeoxynucleotides directed to the human papillomavirus type 16 E6 gene*, Antisense Nucleic Acid Drug Dev., 9(5):441-50 [1999]; Im, S. A., et al., *Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo*, Cancer Res., 59(4):895-900 [1999]; Maeshima, Y. et al., *Antisense oligonucleotides to proliferating cell nuclear antigen and Ki-67 inhibit human mesangial cell proliferation*, J. Am. Soc. Nephrol., 7(10):2219-29 [1996]; Chen, D. S. et al., *Retroviral Vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice*, Hum. Gene Ther., 8(14):1667-74 [1997]; Hirao, T. et al., *Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer*, Cancer Gene Ther., 6(5):423-7 [1999]; Wang, X. Y. et al., *Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells*, Exp. Cell Res., 250(1):253-63 [1999]; Sacco, M.G. et al., *In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice*, Gene Ther., 5(3):388-93 [1998]; Leonetti, C. et al., *Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice*, J. Natl. Cancer Inst., 25 88(7):419-29 [1996]; Laird, A. D. et al., *Inhibition of tumor growth in liver epithelial cells transfected with a transforming growth factor alpha antisense gene*, Cancer Res. 54(15):4224-32 (Aug 1, 1994); Yazaki, T. et al., *Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide*, Mol. Pharmacol., 50(2):236-42 [1996]; Ho, P. T. et al., *Antisense oligonucleotides as therapeutics for malignant diseases*, Semin. Oncol., 24(2):187-202 [1997]; Muller, M. et al., *Antisense phosphorothioate*

oligodeoxynucleotide down-regulation of the insulin-like growth factor I receptor in ovarian cancer cells, Int. J. Cancer, 77(4):567-71 [1998]; Elez, R. et al., *Polo-like kinase, a new target for antisense tumor therapy*, Biochem. Biophys. Res. Commun., 269(2):352-6 [2000]; Monia, B. P. et al., *Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase*, Nat. Med., 2(6):668-75 [1996]).

In other embodiments of the inventive method, the inventive composition comprises a PTTG carboxy-terminal-related polynucleotide that is not contained in an expression vector, for example, a synthetic antisense oligonucleotide, such as a phosphorothioate oligodeoxynucleotide. Synthetic antisense oligonucleotides, or other antisense chemical structures designed to recognize and selectively bind to mRNA, are constructed to be complementary to portions of the *PTTG* coding strand, for example, to coding sequences shown in SEQ ID NOS:1, 3, 10, 15, 18, or 19 (Tables 1-6 below). By preventing translational expression of at least part of the *PTTG* 3' coding region, an antisense PTTG carboxy-terminal-related polynucleotide is useful, in accordance with the inventive method, to prevent expression of PTTG protein that is functional in mediating neoplastic cellular proliferation and/or transformation.

In preferred embodiments of the method of inhibiting neoplastic cellular proliferation and/or transformation, the composition also comprises an uptake-enhancing agent as further described herein. Inventive compositions, containing the uptake-enhancing agent complexed with a *PTTG*-specific polynucleotide, are designed to be capable of passing through the cell membrane in order to enter the cytoplasm of the cell by virtue of physical and chemical properties. In addition, the composition can be designed for delivery only to certain selected cell populations by targeting the composition to be recognized by specific cellular uptake mechanisms which take up the *PTTG*-specific polynucleotides only within select cell populations. For example, the composition can include a receptor agonist to bind to a receptor found only in a certain cell type.

The inventive composition can also optionally contain one or more pharmaceutically acceptable carrier(s). As used herein, the term "acceptable carrier" encompasses any of the standard pharmaceutical carriers. The carrier can be an organic or inorganic carrier or excipient, such as water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents. The active ingredient(s) can optionally be compounded in a composition formulated, for example, with non-toxic, pharmaceutically acceptable carriers for infusions,

tablets, pellets, capsules, solutions, emulsions, suspensions, and any other form suitable for use.

Such carriers also include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, normal saline, phosphate buffered saline and other carriers suitable
 5 for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes can be used as appropriate.

PTTG-specific polynucleotides, including *PTTG* carboxy-terminal-related polynucleotides, are determined by base sequence similarity or homology to known mammalian *PTTG*-specific nucleotide sequences. Base sequence homology is determined by conducting a base sequence
 10 similarity search of a genomics data base, such as the GenBank database of the National Center for Biotechnology Information (NCBI; www.ncbi.nlm.nih.gov/BLAST/), using a computerized algorithm, such as PowerBLAST, QBLAST, PSI-BLAST, PHI-BLAST, gapped or ungapped BLAST, or the "Align" program through the Baylor College of Medicine server (www.hgsc.bcm.tmc.edu/seq_data). (E.g., Altschul, S.F., *et al.*, *Gapped BLAST and PSI-BLAST: a new generation of protein database search programs*, Nucleic Acids Res. 25(17):3389-402
 15 [1997]; Zhang, J., & Madden, T.L., *PowerBLAST: a new network BLAST application for interactive or automated sequence analysis and annotation*, Genome Res. 7(6):649-56 [1997]; Madden, T.L., *et al.*, *Applications of network BLAST server*, Methods Enzymol. 266:131-41 [1996]; Altschul, S.F., *et al.*, *Basic local alignment search tool*, J. Mol. Biol. 215(3):403-10
 20 [1990]). Preferably, a *PTTG*-specific polynucleotide sequence is at least 5 to 30 contiguous nucleotides long, more preferably at least 6 to 15 contiguous nucleotides long, and most preferably at least 7 to 10 contiguous nucleotides long. Preferably, the inventive *PTTG* carboxy-terminal-related polynucleotide is at least about 45 contiguous nucleotides long.

Preferred examples of *PTTG*-specific coding sequences include the sequence for human
 25 *PTTG* (*hPTTG* or *PTTG1*). The *PTTG1* peptide is encoded by the open reading frame at nucleotide positions 95 through 700 of human *PTTG1* gene sequence SEQ. ID.NO.:3 (Table 1 below).

Table 1. *PTTG1* gene sequence.

1 ATGGCCGCGA GTTGTGGTTT AAACCAGGAG TGCCGCGCGT CCGTTCACCG
 51 CGGCCTCAGA TGAATGCGGC TGTTAAGACC TGCAATAATC CAGAATGGCT
 101 ACTCTGATCT ATGTTGATAA GGAAAATGGA GAACCAGGCA CCCGTGTGGT
 151 TGCTAAGGAT GGGCTGAAGC TGGGGTCTGG ACCTTCAATC AAAGCCTTAG
 5 201 ATGGGAGATC TCAAGTTTCA ACACCACGTT TTGGCAAAAC GTTCGATGCC
 251 CCACCAGCCT TACCTAAAGC TACTAGAAAG GCTTTGGGAA CTGTCAACAG
 301 AGCTACAGAA AAGTCTGTAA AGACCAAGGG ACCCCTCAAA CAAAAACAGC
 351 CAAGCTTTTC TGCCAAAAAG ATGACTGAGA AGACTGTAA AGCAAAAAGC
 401 TCTGTTCTG CCTCAGATGA TGCCTATCCA GAAATAGAAA AATTCTTTCC
 10 451 CTTCAATCCT CTAGACTTTG AGAGTTTGA CCTGCCTGAA GAGCACCAGA
 501 TTGCGCACCT CCCCTTGAGT GGAGTGCTC TCATGATCCT TGACGAGGAG
 551 AGAGAGCTTG AAAAGCTGTT TCAGCTGGGC CCCCTTCAC CTGTGAAGAT
 601 GCCCTCTCCA CCATGGGAAT CCAATCTGTT GCAGTCTCCT TCAAGCATTG
 651 TGTCGACCCT GGATGTTGAA TTGCCACCTG TTTGCTGTGA CATAGATATT
 15 701 TAAATTTCTT AGTGCTTCAG AGTTTGTGTG TATTTGTATT AATAAAGCAT
 751 TCTTTAACAG ATAAAAAAAA AAAAAAAAAA (SEQ. ID. NO.:3).

The 3' coding region of *PTTG1* includes the following 168-nucleotide sequence, which corresponds to nucleotide positions 533 through 700 of SEQ. ID. NO.:3, shown in Table 2 below.

Table 2. Portion of 3' coding region of *PTTG1*

1 ATGATCCTTG ACGAGGAGAG AGAGCTTGAA AAGCTGTTTC AGCTGGGCCC
 51 CCCTTCACCT GTGAAGATGC CCTCTCCACC ATGGGAATCC AATCTGTTGC
 101 AGTCTCCTTC AAGCATTCTG TCGACCCTGG ATGTTGAATT GCCACCTGTT
 25 151 TGCTGTGACA TAGATATT (SEQ.ID. NO.:10).

Another useful example of a *PTTG*-specific coding sequence is a sequence that encodes a rat *PTTG* peptide, including nucleotide positions 293 through 889 of SEQ. ID. NO.:1 (Table 3

below).

Table 3. Rat *PTTG* sequence.

	AATTCGGCAC GAGCCAACCT TGAGCATCTG ATCCTCTTGG CTTCTCCTTC CTATCGCTGA	60
	GCTGGTAGGC TGGAGACAGT TGTTTGGGTG CCAACATCAA CAAACGATTT CTGTAGTTTA	120
5	GCGTTTATGA CCCTGCGGTG AAGATTTAAG GTCTGGATTA AGCCTGTTGA CTTCTCCAGC	180
	TACTTCTAAA TTTTGTGCA TAGGTGCTCT GGTCTCTGTT GCTGCTTAGT TCTTCCAGCC	240
	TTCCTCAATG CCAGTTTAT AATATGCAGG TCTCTCCCCT CAGTAATCCA GG ATG	295
	GCT ACT CTG ATC TTT GTT GAT AAG GAT AAC GAA GAG CCA GGC AGC CGT	343
	TTG GCA TCT AAG GAT GGA TTG AAG CTG GGC TCT GGT GTC AAA GCC TTA	391
10	GAT GGG AAA TTG CAG GTT TCA ACG CCA CGA GTC GGC AAA GTG TTC GGT	439
	GCC CCA GGC TTG CCT AAA GCC AGC AGG AAG GCT CTG GGA ACT GTC AAC	487
	AGA GTT ACT GAA AAG CCA GTG AAG AGT AGT AAA CCC CTG CAA TCG AAA	535
	CAG CCG ACT CTG AGT GTG AAA AAG ATC ACC GAG AAG TCT ACT AAG ACA	583
	CAA GGC TCT GCT CCT GCT CCT GAT GAT GCC TAC CCA GAA ATA GAA AAG	631
15	TTC TTC CCC TTC GAT CCT CTA GAT TTT GAG AGT TTT GAC CTG CCT GAA	679
	GAG CAC CAG ATC TCA CTT CTC CCC TTG AAT GGA GTG CCT CTC ATG ATC	727
	CTG AAT GAA GAG AGG GGG CTT GAG AAG CTG CTG CAC CTG GAC CCC CCT	775
	TCC CCT CTG CAG AAG CCC TTC CTA CCG TGG GAA TCT GAT CCG TTG CCG	823
	TCT CCT CCC AGC GCC CTC TCC GCT CTG GAT GTT GAA TTG CCG CCT GTT	871
20	TGT TAC GAT GCA GAT ATT TAAACGTCTT ACTCCTTTAT AGTTTATGTA	919
	AGTTGTATTA ATAAAGCATT TGTGTGTA AAAA AAAAAA AAAACTCGAG AGTAC	974
	(SEQ. ID. NO.:1)	

The 3' coding region of rat *PTTG* includes the following 168-nucleotide sequence, which corresponds to nucleotide positions 722 through 889 of SEQ. ID. NO.:1, shown in Table 4

below.

Table 4. Portion of 3' coding region of rat *PTTG*.

ATG ATC CTG AAT GAA GAG AGG GGG CTT GAG AAG CTG CTG CAC CTG GAC	48
CCC CCT TCC CCT CTG CAG AAG CCC TTC CTA CCG TGG GAA TCT GAT CCG	96

CEDAR-44649

PATENT

TTG CCG TCT CCT CCC AGC GCC CTC TCC GCT CTG GAT GTT GAA TTG CCG

144

CCT GTT TGT TAC GAT GCA GAT ATT

168

(SEQ. ID. NO.:18).

- 5 Another useful example of a *PTTG*-specific coding sequence is a sequence that encodes a murine PTTG peptide, including nucleotide positions 304 through 891 of SEQ. ID. NO.:15 (Table 5 below).

Table 5. Murine *PTTG* sequence.

1 TCTTGAACCTT GTTATGTAGC AGGAGGCCAA ATTTGAGCAT CCTCTTGGCT TCTCTTTATA
 61 GCAGAGATTG TAGGCTGGAG ACAGTTTTGA TGGGTGCCAA CATAAACTGA TTTCTGTAAG
 121 AGTTGAGTGT TTTATGACCC TGGCGTGCAG ATTTAGGATC TGGATTAAGC CTGTTGACTT
 5 181 CTCCAGCTAC TTATAAATTT TTGTGCATAG GTGCCCTGGG TAAAGCTTGG TCTCTGTTAC
 241 TGCCTAGTTT TTCCAGCCGT CTCAATGCCA ATATTCAGGC TCTCTCCCTT AGAGTAATCC
 301 AGAATGGCTA CTCTTATCTT TGTTGATAAG GATAATGAAG AACCCGGCCG CCGTTTGGCA
 361 TCTAAGGATG GGTGTAAGCT GGGCACTGGT GTCAAGGCCT TAGATGGGAA ATTGCAGGTT
 421 TCAACGCCTC GAGTCGGCAA AGTGTTCAT GCTCCAGCCG TGCCTAAAGC CAGCAGAAAG
 10 481 GCTTTGGGGA CAGTCAACAG AGTTGCCGAA AAGCCTATGA AGACTGGCAA ACCCCTCCAA
 541 CCAAAACAGC CGACCTTGAC TGGGAAAAAG ATCACCAGAGA AGTCTACTAA GACACAAAGC
 601 TCTGTTCTTG CTCCTGATGA TGCCCTACCCA GAAATAGAAA AGTTCTTCCC TTTCAATCCT
 661 CTAGATTTTG ACCTGCCTGA GGAGCACCAG ATCTCACTTC TCCCCTTGAA TGGCGTGCCT
 721 CTCATCACCC TGAATGAAGA GAGAGGGCTG GAGAAGCTGC TGCATCTGGG CCCCCCTAGC
 15 781 CCTCTGAAGA CACCCTTTCT ATCATGGGAA TCTGATCCGC TGTACTCTCC TCCCAGTGCC
 841 CTCTCCACTC TGGATGTTGA ATTGCCGCCT GTTTGTTACG ATGCAGATAT TTAAACTTCT
 901 TACTTCTTTG TAGTTTCTGT ATGTATGTTG TATTAATAAA GCATT (SEQ. ID. NO.:15).

The 3' coding region of murine *PTTG* includes the following 168-nucleotide sequence,
 20 which corresponds to nucleotide positions 724 through 891 of SEQ. ID. NO.:15, shown in Table
 6 below.

Table 6. Portion of 3' coding region of murine *PTTG*.

ATCACCTGA ATGAAGAGAG AGGCTGGAG AAGCTGCTGC ATCTGGGCCC CCCTAGCCCT

60

CTGAAGACAC CCTTTCTATC ATGGAATCT GATCCGCTGT ACTCTCTCC CAGTGCCCTC 120

TCCACTCTGG ATGTTGAATT GCCGCCTGTT TGTTACGATG CAGATATT

168

(SEQ. ID. NO.:19).

5 Inventive PTTG-C-related polynucleotides having nucleotides sequences of SEQ. ID.NOS.:10, 18, or 19, degenerate coding sequences, or sequences complementary to any of these, are merely illustrative of useful PTTG carboxy-terminal-related polynucleotides. Other useful PTTG carboxy-terminal-related polynucleotides are functional fragments of any of SEQ. ID. NOS.:10, 18, or 19 at least about 45 contiguous nucleotides long, degenerate coding
10 sequences, or sequences complementary to any of these, the presence of which in the cell can function to downregulate endogenous *PTTG* expression and/or PTTG function, which functionality can be determined by routine screening.

As used herein, the term "degenerate" refers to codons that differ in at least one nucleotide from a reference nucleic acid, e.g., SEQ ID NOS:1, 3, 10, 15, 18, or 19, but encode the same
15 amino acids as the reference nucleic acid. For example, codons specified by the triplets "UCU", "UCC", "UCA", and "UCG" are degenerate with respect to each other since all four of these codons encode the amino acid serine.

Other useful polynucleotides include nucleic acids or other polynucleotides, that differ in sequence from the sequences shown in SEQ ID NO:1, SEQ. ID. NO.:3, SEQ. ID. NO.:10, SEQ.
20 ID. NO.:15, SEQ. ID. NO.:18, and SEQ. ID. NO.:19, but which when expressed in a cell, result in the same phenotype. Phenotypically similar nucleic acids are also referred to as "functionally equivalent nucleic acids". As used herein, the phrase "functionally equivalent nucleic acids" encompasses nucleic acids characterized by slight and non-consequential sequence variations that will function in substantially the same manner, compared to any of the detailed nucleotide
25 sequences disclosed herein, to produce PTTG protein functional with respect to inducing neoplastic cellular proliferation and/or transformation, or PTTG-C peptide(s) functional with respect to inhibition of neoplastic cellular proliferation and/or transformation, and/or polypeptide products functional with respect to immunogenicity. Such polynucleotides can have substantially the same coding sequences as the reference sequences, encoding the amino acid sequence as set
30 forth in SEQ. ID. NO.:2, SEQ. ID. NO.:4, SEQ. ID. NO.:9, SEQ. ID. NO.:14, SEQ. ID. NO.:16,

or SEQ. ID. NO.:17 or a larger amino acid sequence including SEQ. ID. NO.:2, SEQ. ID. NO.:4, SEQ. ID. NO.:9, SEQ. ID. NO.:14, SEQ. ID. NO.:16, or SEQ. ID. NO.:17. As employed herein, the term “substantially the same nucleotide sequence” refers to DNA having sufficient identity to the reference polynucleotide, such that it will hybridize to the reference nucleotide
5 under moderately stringent hybridization conditions. In other embodiments, DNA having “substantially the same nucleotide sequence” as the reference nucleotide sequence has at least about 60% identity with respect to the reference nucleotide sequence. DNA having at least 70%, more preferably at least 90%, yet more preferably at least 95%, identity to the reference nucleotide sequence is preferred.

10 In preferred embodiments, functionally equivalent nucleic acids encode polypeptides or peptide fragments that are the same as those disclosed herein or that have conservative amino acid variations, or that encode larger polypeptides that include SEQ. ID. NO.:2, SEQ. ID. NO.:4, SEQ. ID. NO.:9, or SEQ. ID. NO.:14, SEQ. ID. NO.:16, or SEQ. ID. NO.:17, or fragments of any of these that are biologically functional fragments with respect to inhibiting neoplastic cellular
15 proliferation and/or transformation. For example, conservative variations include substitution of a non-polar residue with another non-polar residue, or substitution of a charged residue with a similarly charged residue. These variations include those recognized by skilled artisans as those that do not substantially alter the tertiary structure of the protein.

Useful polynucleotides can be produced by a variety of methods well-known in the art, e.g.,
20 by employing PCR and other similar amplification techniques, using oligonucleotide primers specific to various regions of SEQ ID NOS:1, 3, 10, 15, 18, 19, or functionally equivalent polynucleotide sequences. Other synthetic methods for producing polynucleotides or oligonucleotides of various lengths are also well known.

In accordance with the method, preferred polynucleotides hybridize under moderately
25 stringent, preferably high stringency, conditions to substantially the entire sequence, or substantial portions (i.e., typically at least 15-30 nucleotide) of the nucleic acid sequence set forth in SEQ ID NOS:1, 3, 10, 15, 18, or 19, or to complementary sequences.

The phrase “stringent hybridization” is used herein to refer to conditions under which annealed hybrids, or at least partially annealed hybrids, of polynucleic acids or other
30 polynucleotides are stable. As known to those of skill in the art, the stability of hybrids is

reflected in the melting temperature (T_m) of the hybrids. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridization reaction is performed under conditions of relatively low stringency, followed by washes of varying, but higher, stringency. Reference to hybridization stringency relates to such washing conditions.

5 As used herein, the phrase "moderately stringent hybridization" refers to conditions that permit target-DNA to bind a complementary nucleic acid that has about 60% sequence identity or homology, preferably about 75% identity, more preferably about 85% identity to the target DNA; with greater than about 90% identity to target-DNA being especially preferred. Preferably, moderately stringent conditions are conditions equivalent to hybridization in 50% formamide, 5
10 x Denhart's solution, 5 x SSPE, 0.2% SDS at 42°C, followed by washing in 0.2 x SSPE, 0.2% SDS, at 65°C.

The phrase "high stringency hybridization" refers to conditions that permit hybridization of only those nucleic acid sequences that form stable hybrids in 0.018 M NaCl at 65°C (i.e., if a hybrid is not stable in 0.018 M NaCl at 65°C, it will not be stable under high stringency
15 conditions, as contemplated herein). High stringency conditions can be provided, for example, by hybridization in 50% formamide, 5X Denhart's solution, 5X SSPE, 0.2% SDS at 42°C, followed by washing in 0.1 x SSPE, and 0.1% SDS at 65°C.

The phrase "low stringency hybridization" refers to conditions equivalent to hybridization in 10% formamide, 5X Denhart's solution, 6 x SSPE, 0.2% SDS at 42°C, followed by washing
20 in 1 x SSPE, 0.2% SDS, at 50°C. Denhart's solution and SSPE (see, e.g., Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory Press [1989]) are well known to those of skill in the art as are other suitable hybridization buffers.

The PTTG carboxy-terminal-related polynucleotide can be, but is not necessarily, of homologous origin with respect to the cell, due to the relatively high degree of sequence
25 homology among mammalian *PTTG* sequences. PTTG carboxy-terminal-related polynucleotides of heterologous mammalian origin with respect to the cell is also useful. Thus, for example, in accordance with the inventive method, a human PTTG-C-encoding sequence functions to down regulate endogenous *PTTG* expression and/or PTTG function in cells of non-human mammalian origin, such as murine or rat cells, and vice versa.

30 In preferred embodiments of the method of inhibiting neoplastic cellular proliferation and/or

transformation of a mammalian cell, the polynucleotide is complexed with a cellular uptake-enhancing agent, in an amount and under conditions sufficient to enter the cell. An "uptake-enhancing" agent, as utilized herein, means a composition of matter for enhancing the uptake of exogenous polynucleotides, such as DNA segment(s), nucleic acid analogs, or nucleic acid constructs, into a eukaryotic cell, preferably a mammalian cell, and more preferably a human cell. The enhancement is measured relative to the polynucleotide uptake in the absence of the uptake-enhancing agent, in the process of transfecting or transducing the cell. Complexation with uptake-enhancing agent(s) generally augments the uptake of a polynucleotide into the cell and/or reduces its breakdown by nucleases during its passage through the cytoplasm.

In accordance with preferred embodiments of the inventive method, PTTG carboxy-terminal-related polynucleotides or PTTG-C peptides are complexed with an uptake-enhancing agent. "Complexed" means that the polynucleotide or peptide is a constituent or member of a complex, mixture, or adduct resulting from chemical binding or bonding between and/or among the other constituents, including the cellular uptake-enhancing agent(s), and/or their moieties. Chemical binding or bonding can have the nature of a covalent bond, ionic bond, hydrogen bond, hydrophobic bond, or any combination of these bonding types linking the constituents of the complex at any of their parts or moieties, of which a constituent can have one or a multiplicity of moieties of various sorts. Not every constituent of a complex need be bound to every other constituent, but each constituent has at least one chemical bond with at least one other constituent of the complex. Constituents can include, but are not limited to, molecular compounds of a polar, non-polar, or detergent character; ions, including cations, such as, but not limited to, Na^+ , K^+ , Li^+ , Ca^{2+} , Mg^{2+} , Fe^{2+} , Fe^{3+} , Zn^{2+} , Cu^+ , Cu^{2+} , and/or NH_4^+ , or anions, such as, but not limited to Cl^- , Br^- , F^- , NO_3^- , NO_2^- , NO^- , HCO_3^- , CO_3^{2-} , SO_4^{2-} , and/or PO_4^{3-} ; biological molecules, such as proteins, oligopeptides, polypeptides, oligonucleotides, nucleic acids, nucleic acid constructs, plasmids, viral particles; an/or organic polymers and co-polymers.

PTTG carboxy-terminal-related polynucleotides or PTTG-C peptides can be, but are not necessarily, directly bound to the cellular uptake-enhancing agent. For example, the polynucleotide can be contained in an expression vector or other nucleic acid construct, which vector or other construct is bound to the uptake-enhancing agent at some moiety or part of the vector or construct not directly linked to the PTTG carboxy-terminal-related polynucleotide; for

purposes of the present invention, the PTTG carboxy-terminal-related polynucleotide is still “complexed” with the uptake-enhancing agent, although not being directly bound to the uptake-enhancing agent by a chemical bond. As long as the polynucleotide and the uptake enhancing agent are both constituents or members of the same complex, an indirect chemical linkage suffices. An example with respect to PTTG-C peptides, is an intervening third peptide sequence linking a first PTTG-C peptide segment with a second cell uptake-enhancing and/or importation-competent peptide segment. The first and second peptide segments, indirectly linked, are “complexed” for purposes of the invention.

Examples of uptake-enhancing agents usefully complexed with the polynucleotide include cationic or polycationic lipid-DNA or liposome-DNA complexes (“lipoplexes”). Such lipoplexes can, optionally, also be coated with serum albumin or formulated as large-sized colloiddally unstable complexes to further enhance transfection efficiency; the presence of calcium di-cations (Ca^{2+}) can also enhance lipid-based transfection efficiency. (E.g., Simoes, S. *et al.*, *Human serum albumin enhances DNA transfection by lipoplexes and confers resistance to inhibition by serum*, Biochim. Biophys. Acta 1463(2):459-69 [2000]; Turek, J. *et al.*, *Formulations which increase the size of lipoplexes prevent serum-associated inhibition of transfection*, J. Gene Med. 2(1):32-40 [2000]; Zudam, N.J. *et al.*, *Lamellarity of cationic liposomes and mode of preparation of lipoplexes affect transfection efficiency*, Biochim. Biophys. Acta 1419(2):207-20 [1999]; Lam, A.M. and Cullis, P.R., *Calcium enhances the transfection potency of plasmid DNA-cationic liposome complexes*, Biochim. Biophys. Acta 1463(2):279-290 [2000]).

Inventive compositions can include negatively charged ternary complexes of cationic liposomes, transferrin or fusigenic peptide(s) or poly(ethylenimine). (E.g., Simoes, S. *et al.*, *Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides*, Gene Ther. 5(7):955-64 [1998]). Liposomal uptake-enhancing agents complexed with inventive polynucleotide(s) can also be encapsulated in polyethylene glycol (PEG), FuGENE6, or the like. (E.g., Saravolac, E.G., *et al.*, *Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity*, J. Drug Target 7(6):423-37 [2000]; Yu, R.Z. *et al.*, *Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes*, Pharm. Res. 16(8):1309-15 [1999]; Tao, M. *et al.*,

Specific inhibition of human telomerase activity by transfection reagent, FuGENE6-antisense phosphorothioate oligonucleotide complex in HeLa cells, FEBS Lett 454(3):312-6 [1999]).

In some embodiments, the uptake of antisense oligonucleotides is also enhanced by complexation with biocompatible polymeric or co-polymeric nanoparticles, for example, comprising alginate, aminoalkylmethacrylate, methylmethacrylate, polymethylmethacrylate, methylaminoethyl-methacrylate, polyalkylcyanoacrylate (e.g., polyhexylcyanoacrylate), or the like. (E.g., Aynie, I. *et al.*, *Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides*, Antisense Nucleic Acid Drug Dev. 9(3):301-12 [1999]; Zimmer, A., *Antisense oligonucleotide delivery with polyhexylcyanoacrylate nanoparticles as carriers*, Methods 18(3):286-95, 322 [1999]; Berton, M. *et al.*, *Highly loaded nanoparticulate carrier using an hydrophobic antisense oligonucleotide complex*, Eur. J. Pharm. Sci. 9(2):163-70 [1999]; Zobel, H.P. *et al.*, *Evaluation of aminoalkylmethacrylate nanoparticles as colloidal drug carrier systems. Part II: characterization of antisense oligonucleotides loaded copolymer nanoparticles*, Eur. J. Pharm. Biopharm. 48(1):1-12 [1999]; Fattal, E. *et al.*, *Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides*, J. Controlled Release 53(1-3):137-43 [1998]).

Other useful uptake-enhancing agents for complexing with polynucleotides include starburst polyamidoamine (PAMAM) dendrimers. (E.g., Yoo, H. *et al.*, *PAMAM dendrimers as delivery agents for antisense oligonucleotides*, Pharm. Res. 16(12):1799-804 [1999]; Bielinska, A.U. *et al.*, *Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo*, Biomaterials 21(9):877-87 [2000]; Bielinska, A.U. *et al.*, *DNA complexing with polyamidoamine dendrimers: implications for transfection*, Bioconjug. Chem. 10(5):843-50 [1999]; Bielinska, A.U. *et al.*, *Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers*, Nucleic Acid Res. 24(11):2176-82 [1996]; Kukowska-Latallo, J.F. *et al.*, *Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers*, Proc. Natl. Acad. Sci. USA 93(10):4897-902 [1996]; Delong, R. *et al.*, *Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery*, J. Pharm. Sci. 86(6):762-64 [1997]).

Other preferred uptake-enhancing agents include lipofectin, lipfectamine, DIMRIE C,

Superfect, Effectin (Qiagen), unifectin, maxifectin, DOTMA, DOGS (Transfectam; dioctadecylamidoglycylspermine), DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine), DOTAP (1,2-dioleoyl-3-trimethylammonium propane), DDAB (dimethyl dioctadecylammonium bromide), DHDEAB (N,N-di-n-hexadecyl-N,N-dihydroxyethyl ammonium bromide), HDEAB (N-n-hexadecyl-N,N-dihydroxyethylammonium bromide), polybrene, or poly(ethylenimine) (PEI), and /or peptides, such as polylysine, protamine, pK17, peptide K8, and peptide p2. (E.g., Ferkol, Jr. *et al.*, U.S. Patent Nos., 5,972,900 and 5,972,901; Vaysse, L. and Arveiler, B., *Transfection using synthetic peptides: comparison of three DNA-compacting peptides and effect of centrifugation*, Biochim. Biophys. Acta 1474(2):244-50 [2000]; Ni, Y.H. *et al.*, *Protamine enhance the efficiency of liposome-mediated gene transfer in a cultured human hepatoma cell line*, J. Formos. Med. Assoc. 98(8):562-66 [1999]; Banerjee, R. *et al.*, *Novel series of non-glycerol-based cationic transfection lipids for use in liposomal gene delivery*, J. Med. Chem. 42(21):4292-99 [1999]; Godbey, W.T. *et al.*, *Improved packing of poly(ethylenimine)/DNA complexes increases transfection efficiency*, Gene Ther. 6(8):1380-88 [1999]; Kichler, A *et al.*, *Influence of the DNA complexation medium on the transfection efficiency of lipospermine/DNA particles*, Gene Ther. 5(6):855-60 [1998]; Birchaa, J.C. *et al.*, *Physico-chemical characterisation and transfection efficiency of lipid-based gene delivery complexes*, Int. J. Pharm. 183(2):195-207 [1999]). These non-viral cellular uptake-enhancing agents have the advantage that they facilitate stable integration of xenogeneic DNA sequences into the vertebrate genome, without size restrictions commonly associated with virus-derived transfecting or transducing agents.

Another example, a viral cellular uptake-enhancing agent, is the adenovirus enhanced transferrin-polylysine-mediated gene delivery system has been described and patented by Curiel *et al.* (Curiel D.T., *et al.*, *Adenovirus enhancement of transferrin-polylysine-mediated gene delivery*, PNAS USA 88: 8850-8854 (1991). The delivery of DNA depends upon endocytosis mediated by the transferrin receptor (Wagner *et al.*, *Transferrin-polycation conjugates as carriers for DNA uptake into cells*, PNAS (USA) 87: 3410-3414 (1990). In addition this method relies on the capacity of adenoviruses to disrupt cell vesicles, such as endosomes and release the contents entrapped therein. This system can enhance the gene delivery to mammalian cells by as much as 2,000 fold over other methods.

A particularly useful uptake enhancing agent for delivery of polynucleotides to human T-

lymphocytes is a "tamed" (i.e., lacking native viral genes required for immunodeficiency pathogenesis and/or virulence) Human Immunodeficiency Virus (HIV) vector, which mediates uptake via the CD4 molecule. A variety of such tamed viral vectors, binding with CD4 and/or with other T-lymphocyte markers, are also known in the art.

5 The amount of each component of the composition is chosen so that the gene modification, e.g., by transfection or transduction, of a mammalian cell is optimized. Such optimization requires no more than routine experimentation. The ratio of polynucleotide to lipid is broad, preferably about 1:1, although other effective proportions can also be utilized depending on the type of lipid uptake-enhancing agent and polynucleotide utilized. (E.g., Banerjee, R. *et al.*
10 [1999]; Jaaskelainen, I. *et al.*, *A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides*, Eur. J. Pharm. Sci. 10(3):187-193 [2000]; Sakurai, F. *et al.*, *Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene*
15 *expression*, J. Controlled Release 66(2-3):255-69 [2000]).

A suitable amount of the inventive polynucleotide to be delivered to the cells, in accordance with the method, preferably ranges from about 0.1 nanograms to about 1 milligram per gram of tumor tissue, in vivo, or about 0.1 nanograms to about 1 microgram per 5000 cells, in vitro. Suitable amounts for particular varieties of PTTG-C-related polynucleotides and/or cell types
20 and/or for various mammalian subjects undergoing treatment, can be determined by routine experimentation. For example, malignant cell lines, such as MCF-7 or HeLa, typically are more efficiently transfected by the inventive PTTG-C-related polynucleotides than non-malignant cell lines. Also, those skilled in the art are aware that there is typically considerable variability among individual cancer patients to any single treatment regimen, therefore, the practitioner will tailor
25 any embodiment of the inventive method to each individual patient as appropriate.

In some preferred embodiments, the polynucleotide can be delivered into the mammalian cell, either in vivo or in vitro using suitable expression vectors well-known in the art (e.g., retroviral vectors, adenovirus vectors, and the like). In addition, to inhibit the in vivo expression of *PTTG*, the introduction by expression vector of the antisense strand of a DNA encoding a
30 PTTG-C peptide is contemplated.

Suitable expression vectors are well-known in the art, and include vectors capable of expressing DNA operatively linked to a regulatory sequence, such as a promoter region that is capable of regulating expression of such DNA. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the inserted DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

Exemplary, eukaryotic expression vectors, include the cloned bovine papilloma virus genome, the cloned genomes of the murine retroviruses, and eukaryotic cassettes, such as the pSV-2 gpt system (described by Mulligan and Berg, 1979, Nature Vol. 277:108-114) the Okayama-Berg cloning system (Mol. Cell Biol. Vol. 2:161-170, 1982), pGAL4, pCI (e.g., pCI-neo), and the expression cloning vector described by Genetics Institute (Science Vol. 228:810-815, 1985), are available which provide substantial assurance of at least some expression of the protein of interest in the transformed mammalian cell.

Particularly preferred are vectors which contain regulatory elements that can be linked to the inventive PTTG-encoding DNAs, such as a PTTG-C-encoding DNA segment, for transfection of mammalian cells. Examples are cytomegalovirus (CMV) promoter-based vectors such as pcDNA1 (Invitrogen, San Diego, CA), MMTV promoter-based vectors such as pMAMNeo (Clontech, Palo Alto, CA) and pMSG (Pharmacia, Piscataway, NJ), and SV40 promoter-based vectors such as pSV β (Clontech, Palo Alto, CA).

In one embodiment of the present invention, adenovirus-transferrin/polylysine-DNA (TfAdpl-DNA) vector complexes (Wagner et al., 1992, PNAS, USA, 89:6099-6103; Curiel et al., 1992, Hum. Gene Therapy, 3:147-154; Gao et al., 1993, Hum. Gene Ther., 4:14-24) are employed to transduce mammalian cells with heterologous *PTTG*-specific nucleic acid. Any of the plasmid expression vectors described herein may be employed in a TfAdpl-DNA complex.

In addition, vectors may contain appropriate packaging signals that enable the vector to be packaged by a number of viral virions, e.g., retroviruses, herpes viruses, adenoviruses, resulting in the formation of a "viral vector."

"Virus", as used herein, means any virus, or transfecting fragment thereof, which can

facilitate the delivery of the polynucleotide into mammalian cells. Examples of viruses which are suitable for use herein are adenoviruses, adeno-associated viruses, retroviruses such as human immune-deficiency virus, lentiviruses, mumps virus, and transfecting fragments of any of these viruses, and other viral DNA segments that facilitate the uptake of the desired DNA segment by, and release into, the cytoplasm of germ cells and mixtures thereof. A preferred viral vector is Moloney murine leukemia virus and the retrovirus vector derived from Moloney virus called vesicular-stomatitis-virus-glycoprotein (VSV-G)-Moloney murine leukemia virus. A most preferred viral vector is a pseudotyped (VSV-G) lentiviral vector derived from the HIV virus. (Naldini *et al.* [1996]). Also, the mumps virus is particularly suited because of its affinity for immature sperm cells including spermatogonia. All of the above viruses may require modification to render them non-pathogenic or less antigenic. Other known viral vector systems, however, are also useful within the confines of the invention.

Viral based systems provide the advantage of being able to introduce relatively high levels of the heterologous nucleic acid into a variety of cells. Suitable viral vectors for introducing inventive *PTTG*-specific polynucleotides into mammalian cells (e.g., vascular tissue segments) are well known in the art. These viral vectors include, for example, Herpes simplex virus vectors (e.g., Geller *et al.*, 1988, *Science*, 241:1667-1669), Vaccinia virus vectors (e.g., Piccini *et al.*, 1987, *Meth. in Enzymology*, 153:545-563; Cytomegalovirus vectors (Mocarski *et al.*, in *Viral Vectors*, Y. Gluzman and S.H. Hughes, Eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1988, pp. 78-84), Moloney murine leukemia virus vectors (Danos *et al.*, 1980, *PNAS, USA*, 85:6469), adenovirus vectors (e.g., Logan *et al.*, 1984, *PNAS, USA*, 81:3655-3659; Jones *et al.*, 1979, *Cell*, 17:683-689; Berkner, 1988, *Biotechniques*, 6:616-626; Cotten *et al.*, 1992, *PNAS, USA*, 89:6094-6098; Graham *et al.*, 1991, *Meth. Mol. Biol.*, 7:109-127), adeno-associated virus vectors, retrovirus vectors (see, e.g., U.S. Patent 4,405,712 and 4,650,764), and the like. Especially preferred viral vectors are the adenovirus and retroviral vectors.

As used herein, "retroviral vector" refers to the well-known gene transfer plasmids that have an expression cassette encoding an heterologous gene residing between two retroviral LTRs. Retroviral vectors typically contain appropriate packaging signals that enable the retroviral vector, or RNA transcribed using the retroviral vector as a template, to be packaged into a viral virion

in an appropriate packaging cell line (see, e.g., U.S. Patent 4,650,764). Retroviral vectors include lentiviral vectors, such as HIV-derived vectors.

Suitable retroviral vectors for use herein are described, for example, in U.S. Patent 5,252,479, and in WIPO publications WO 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO 92/14829, incorporated herein by reference, which provide a description of methods for efficiently introducing nucleic acids into human cells using such retroviral vectors. Other retroviral vectors include, for example, the mouse mammary tumor virus vectors (e.g., Shackleford et al., 1988, PNAS, USA, 85:9655-9659), and the like.

A most preferred embodiment employs a pseudotyped retroviral vector system, which was developed for gene therapy. (Naldini, L., *et al.*, *In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector*, Science 272: 263-267 [1996]), and which is used to transduce mammalian cells. This gene delivery system employs retroviral particles generated by a three-plasmid expression system. In this system a packaging construct contains the human cytomegalovirus (hCMV) immediate early promoter, driving the expression of all viral proteins. The construct's design eliminates the cis-acting sequences crucial for viral packaging, reverse transcription and integration of these transcripts. The second plasmid encodes a heterologous envelope protein (*env*), namely the G glycoprotein of the vesicular stomatitis virus (VSV-G). The third plasmid, the transducing vector (pHR'), contains cis-acting sequences of human immunodeficiency virus (HIV) required for packaging, reverse transcription and integration, as well as unique restriction sites for cloning heterologous complementary DNAs (cDNAs). For example, a genetic selection marker, such as green fluorescent protein (GFP), enhanced green fluorescent protein (EGFP), blue fluorescent protein, yellow fluorescent protein, β -galactosidase, and/or a gene encoding another preselected product is cloned downstream of the hCMV promoter in the HR' vector, and is operatively linked so as to form a transcriptional unit. A VSV-G pseudotyped retroviral vector system is capable of infecting a wide variety of cells including cells from different species and of integrating into the genome. Some retroviruses, i.e., lentiviruses, such as HIV, have the ability to infect non-dividing cells. Lentiviruses have a limited capacity for heterologous DNA sequences, the size limit for this vector being 7-7.5 kilobases (Verma, I.M. and Somia, N., *Gene Therapy – promises, problems and prospects*, Nature 389:239-242 [1997]). *In vivo* experiments with lentiviruses show that expression does not shut

off like other retroviral vectors and that *in vivo* expression in brain, muscle, liver or pancreatic-islet cells, is sustained at least for over six months – the longest time tested so far (Verma and Somia [1997]; Anderson, WF., *Human Gene Therapy*, Nature (Suppl). 392:25-30 [1998]).

"Gene delivery (or transfection) mixture", in the context of this patent, means a selected
5 PTTG carboxy-terminal-related polynucleotide, whether in sense or anti-sense orientation, together with an appropriate vector mixed, for example, with an effective amount of uptake-enhancing agent as described above. (E.g., Clark *et al.*, *Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells*, Cancer Gene Ther. 6(5):437-46 [1999]). For example, the efficiency of adenoviral-, retroviral-, or lentiviral-mediated
10 transduction is enhanced significantly by including a cationic lipid, such as polybrene during the infection.

In peptide-based embodiments of the inventive method of inhibiting neoplastic cellular proliferation and/or transformation, involves delivering an inventive composition comprising a PTTG carboxy-terminal peptide, which is interchangeably designated herein "PTTG-C" or
15 "PTTG C-terminal peptide".

The terms "protein", "peptide", and "polypeptide" are used interchangeably herein. As used herein, the phrase "PTTG" refers to protein member of a mammalian family of PTTG proteins, formerly also known as "pituitary-tumor-specific-gene" (PTSG) proteins, that are able to transform mammalian cells in tissue culture (e.g., NIH 3T3 and the like).

20 In vivo, PTTG proteins are further characterized by having the ability to induce tumor formation, for example, in nude mice (e.g., when transfected into NIH 3T3 and the like). PTTG proteins include naturally occurring allelic variants thereof encoded by mRNA generated by alternative splicing of a primary transcript, and further include fragments thereof which retain at least one native biological activity.

25 The term "biologically active" or "functional", when used herein as a modifier of inventive PTTG protein(s), peptide(s), or fragments thereof, refers to a polypeptide that exhibits at least one of the functional characteristics attributed to PTTG. For example, one biological activity of PTTG is the ability to transform cells in vitro (e.g., NIH 3T3 and the like). Another biological activity is the ability to modulate the activation of mammalian T-lymphocytes, as described herein.
30 Yet another biological activity of PTTG is the ability to induce neoplastic cellular proliferation

(e.g., tumorigenesis) in nude mice (e.g., when transfected into NIH 3T3 cells and the like).

On the other hand, the inventive PTTG-C peptide, as distinct from the full length native PTTG protein, has the biological activity of inhibiting *PTTG* -mediated tumorigenesis in a dominant negative manner. "Dominant negative" is commonly used to describe a gene or protein which has a dominant effect similar to that described genetically, i.e. one copy of the gene gives a mutant phenotypic effect, and a negative effect in that it prevents or has a negative impact on a biological process such as a signal transduction pathway. Thus, PTTG carboxy-terminal peptides have the ability to downregulate intracellular *PTTG* expression and/or endogenous PTTG function. The inventive method is not limited to any particular biochemical, genetic, and/or physiological mechanism(s) by which a PTTG-C peptide exerts its biological activity on *PTTG* expression and/or PTTG function, and any or all such mechanism(s) can contribute to the biological activity of PTTG-C, in accordance with the invention.

Another biological activity of PTTG or PTTG-C peptides is the ability to act as an immunogen for the production of polyclonal and monoclonal antibodies that bind specifically to PTTG and/or PTTG-C. Thus, an inventive nucleic acid encoding PTTG or PTTG-C will encode a polypeptide specifically recognized by an antibody that also specifically recognizes a PTTG protein as described herein. Such activity may be assayed by any method known to those of skill in the art. For example, a test-polypeptide encoded by a *PTTG* cDNA can be used to produce antibodies, which are then assayed for their ability to bind to the protein. If the antibody binds to the test-polypeptide and the protein with substantially the same affinity, then the polypeptide possesses the requisite biological activity with respect to immunogenicity.

In the method of immunosuppressing a mammalian lymphocyte or in the method of inhibiting neoplastic cellular proliferation and/or transformation of a mammalian cell, whether in vitro or in vivo, useful PTTG-C peptides encompass also any fragment of a larger PTTG-C molecule, which fragment retains PTTG-C biological activity with respect to downregulating endogenous *PTTG* expression and/or endogenous PTTG function. Useful PTTG-C peptides are preferably, but not exclusively, about 15 to about 60 contiguous amino acid residues long and comprise one or more proline-rich regions, which are peptide segments having a PXXP motif, where the Xs between the proline (P) residues represent any amino acid residue, including proline. The proline-rich region(s) of the PTTG-C peptide is a potential SH3-binding site.

SH3 binding sites of PTTG protein molecules are useful targets for inhibiting intracellular *PTTG* expression and/or PTTG protein function. Downregulation or inhibition of intracellular *PTTG* expression and/or endogenous PTTG function can be accomplished by blocking specific binding to a SH3-binding site normally present on endogenous PTTG protein molecules, thus

5 interfering with SH3-mediated signal transduction in the cell.

Most preferably, the PTTG-C peptide is derived from a human PTTG, also designated hPTTG or PTTG1 protein. The native human PTTG1 protein is 202 amino acids long, having the following amino acid sequence (Table 7 below; encoded by nucleotide positions 95 through 700 of human *PTTG1* sequence SEQ. ID.NO.:3 and degenerate sequences).

10 Table 7. PTTG1 amino acid sequence.

1 MATLIYVDKE NGEPGTRVVA KDGLKLGSGP SIKALDGRSQ VSTPRFGKTF
 51 DAPPALPKAT RKALGTVNRA TEKSVKTKGP LKQKQPSFSA KKMTEKTVKA
 101 KSSVPASDDA YPEIEKFFPF NPLDFESFDL PEEHQIAHLP LSGVPLMILD
 151 EERELEKLFQ LGPPSPVKMP SPPWESNLLQ SPSSILSTLD VELPPVCCDI
 15 201 DI (SEQ. ID. NO.:4)

The human PTTG1 peptide is also encoded by any degenerate coding sequence encoding the amino acid sequence of SEQ. ID. NO.:4.

A preferred PTTG-C has the amino acid sequence corresponding to amino acid residues 147 through 202 of SEQ. ID. NO.:4 (Table 8 below; encoded by nucleotide positions 533 through 700 of SEQ. ID. NO.:3 or 1-168 of SEQ. ID. NO.:10 and degenerate sequences).

20

Table 8. Human PTTG-C amino acid sequence.

MILDEERELE KLFQLGPPSP VKMPSPPWES NLLQSPSSIL STLDVELPPV CCDIDI
 56
 25 (SEQ. ID. NO.:9).

There are at least two proline-rich regions between amino acid residues 163-173 of SEQ. ID. NO.:4, which correspond to amino acid residues 17 through 27 of SEQ. ID. NO.:9, encoded

by nucleotides 49 through 81 of SEQ. ID. NO.:10 and degenerate sequences. Proline-rich regions are found at amino acid residues 163-167 and 170-173 of SEQ. ID. NO.:4, corresponding to amino acid residues 17-20 and 24-27 of SEQ. ID. NO.:9. Other useful smaller peptide fragments of SEQ. ID. NO.:9 are tested by routine means for their effectiveness in inhibiting

5 neoplastic cellular proliferation and/or transformation of a cell.

Another example of a PTTG protein is a rat PTTG having the following amino acid sequence (Table 9 below; encoded by nucleotide positions 293-889 of SEQ. ID. NO.:1 and degenerate sequences).

Table 9. Rat PTTG amino acid sequence.

10	Met Ala Thr Leu Ile Phe Val Asp Lys Asp Asn Glu Glu Pro Gly Ser	16
	Arg Leu Ala Ser Lys Asp Gly Leu Lys Leu Gly Ser Gly Val Lys Ala	32
	Leu Asp Gly Lys Leu Gln Val Ser Thr Pro Arg Val Gly Lys Val Phe	48
	Gly Ala Pro Gly Leu Pro Lys Ala Ser Arg Lys Ala Leu Gly Thr Val	64
	Asn Arg Val Thr Glu Lys Pro Val Lys Ser Ser Lys Pro Leu Gln Ser	80
15	Lys Gln Pro Thr Leu Ser Val Lys Lys Ile Thr Glu Lys Ser Thr Lys	96
	Thr Gln Gly Ser Ala Pro Ala Pro Asp Asp Ala Tyr Pro Glu Ile Glu	112
	Lys Phe Phe Pro Phe Asp Pro Leu Asp Phe Glu Ser Phe Asp Leu Pro	128
	Glu Glu His Gln Ile Ser Leu Leu Pro Leu Asn Gly Val Pro Leu Met	144
	Ile Leu Asn Glu Glu Arg Gly Leu Glu Lys Leu Leu His Leu Asp Pro	160
20	Pro Ser Pro Leu Gln Lys Pro Phe Leu Pro Trp Glu Ser Asp Pro Leu	176
	Pro Ser Pro Pro Ser Ala Leu Ser Ala Leu Asp Val Glu Leu Pro Pro	192
	Val Cys Tyr Asp Ala Asp Ile	199

(SEQ. ID. NO.:2).

A rat PTTG-C peptide includes amino acid residues 144 through 199 of SEQ. ID. NO.:2, i.e., SEQ. ID. NO.:16 (Table 10 below; encoded by nucleotide positions 722 through 889 of SEQ. ID. NO.:1 or 1-168 of SEQ. ID. NO.:18 and degenerate sequences).

25

Table 10. Rat PTTG-C amino sequence.

	Met Ile Leu Asn Glu Glu Arg Gly Leu Glu Lys Leu Leu His Leu Asp	16
	Pro Pro Ser Pro Leu Gln Lys Pro Phe Leu Pro Trp Glu Ser Asp Pro	32
	Leu Pro Ser Pro Pro Ser Ala Leu Ser Ala Leu Asp Val Glu Leu Pro	48
5	Pro Val Cys Tyr Asp Ala Asp Ile	56
	SEQ. ID. NO.:16	

The amino acid sequence of SEQ. ID. NO.:16 includes proline-rich regions at amino acid residues 17-20, 24-27, and 34-37 (corresponding to amino acid residues 160-163, 167-170, and 177-180 of SEQ. ID. NO.:2).

Another example of a PTTG protein is a murine PTTG having the following amino acid sequence (Table 11 below; encoded by nucleotide positions 304 through 891 of SEQ. ID. NO.:15 and degenerate sequences).

Table 11. Murine PTTG amino acid sequence.

15	1	MATLIFVDKD NEEPGRRLAS KDGLKLGTGV KALDGKLQVS TPRVGKVFNA
	51	PAVPKASRKA LGTVNRVAEK PMKTGKPLQP KQPTLTGKKI TEKSTKTQSS
	101	VPAPDDAYPE IEKFFPFNPL DFDLPEEHQI SLLPLNGVPL ITLNEERGLE
	151	KLLHLGPPSP LKTPFLSWES DPLYSPPSAL STLDVELPPV CYDADI
	SEQ. ID. NO.: 14	

A murine PTTG-C peptide includes amino acid residues 141 through 196 of SEQ. ID. NO.:14, i.e., SEQ. ID. NO.:17 (Table 12 below; encoded by nucleotide positions 724 through 891 of SEQ. ID. NO.:15 or 1-168 of SEQ. ID. NO.:19 and degenerate sequences).

Table 12. Murine PTTG-C amino acid sequence.

ITLNEERGLE KLLHLGPPSP LKTPFLSWES DPLYSPPSAL STLDVELPPV CYDADI 56

(SEQ. ID. NO.:17).

The amino acid sequence of SEQ. ID. NO.:17 includes a proline-rich region at amino acid residues 17-20 (corresponding to amino acid residues 157-160 of SEQ. ID. NO.:14).

Preferred PTTG-C peptides include:

5 (A) peptides having an amino acid sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:16), or (SEQ. ID. NO.:17); or

(B) mammalian PTTG-C peptides having at least about 60% sequence homology with any of the sequences in (A); or

10 (C) peptide fragments of any of the sequences in (A) or (B) that comprise at least 15 contiguous amino acid residues and that function to downregulate endogenous *PTTG* expression and/or PTTG function. Most preferably, the fragment of (C) includes one or more proline-rich regions.

Those of skill in the art will recognize that in other useful PTTG-C peptides numerous residues of any of the above-described PTTG or PTTG-C amino acid sequences can be
15 substituted with other, chemically, sterically and/or electronically similar residues without substantially altering PTTG or PTTG-C biological activity. In addition, larger polypeptide sequences containing substantially the same coding sequences as in SEQ ID NO:2, SEQ. ID. NO.:4, SEQ. ID. NO.:9, SEQ. ID. NO.:14, SEQ. ID. NO.:16, or SEQ. ID. NO.:17 (e.g., splice variants) are contemplated.

20 As employed herein, the term "substantially the same amino acid sequence" refers to amino acid sequences having at least about 60% sequence homology or identity with respect to any of the amino acid sequences described herein ("reference sequences"), and retaining comparable functional and biological activity characteristic of the protein defined by the reference sequences described, particularly with respect to neoplastic cellular proliferation and/or transformation or
25 its inhibition. More preferably, proteins having "substantially the same amino acid sequence" will have at least about 80%, still more preferably about 90% amino acid identity with respect to a reference amino acid sequence; with greater than about 95% amino acid sequence identity being especially preferred. It is recognized, however, that polypeptide containing less than the described levels of sequence identity arising as splice variants or that are modified by conservative

amino acid substitutions are also encompassed within the scope of the present invention. The degree of sequence homology is determined by conducting an amino acid sequence similarity search of a protein data base, such as the database of the National Center for Biotechnology Information (NCBI; www.ncbi.nlm.nih.gov/BLAST/), using a computerized algorithm, such as

5 PowerBLAST, QBLAST, PSI-BLAST, PHI-BLAST, gapped or ungapped BLAST, or the "Align" program through the Baylor College of Medicine server (www.hgsc.bcm.tmc.edu/seq_data). (E.g., Altschul, S.F., *et al.*, *Gapped BLAST and PSI-BLAST: a new generation of protein database search programs*, *Nucleic Acids Res.* 25(17):3389-402 [1997]; Zhang, J., & Madden, T.L., *PowerBLAST: a new network BLAST application for*

10 *interactive or automated sequence analysis and annotation*, *Genome Res.* 7(6):649-56 [1997]; Madden, T.L., *et al.*, *Applications of network BLAST server*, *Methods Enzymol.* 266:131-41 [1996]; Altschul, S.F., *et al.*, *Basic local alignment search tool*, *J. Mol. Biol.* 215(3):403-10 [1990]).

Also encompassed by the terms PTTG protein or PTTG-C peptide, respectively, are

15 biologically functional or active peptide analogs thereof. The term peptide "analog" includes any polypeptide having an amino acid residue sequence substantially identical to a sequence specifically shown herein in which one or more residues have been conservatively substituted with a functionally similar residue and which displays the ability to mimic the biological activity of PTTG or PTTG-C, respectively, particularly with respect to neoplastic cellular proliferation and/or transformation or its inhibition, or with respect to immunosuppressing mammalian lymphocyte cells, as described herein above. Examples of conservative substitutions include the

20 substitution of one non-polar (hydrophobic) residue such as isoleucine, valine, leucine or methionine for another, the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, between glycine and serine, the

25 substitution of one basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue, such as aspartic acid or glutamic acid for another.

The phrase "conservative substitution" also includes the use of a chemically derivatized residue in place of a non-derivatized residue, provided that such polypeptide displays the requisite biological activity.

30 "Chemical derivative" refers to a subject polypeptide having one or more residues

chemically derivatized by reaction of a functional side group. Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups. Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides. Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives. The imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine. Also included as chemical derivatives are those peptides which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acids. For example, 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted for serine; and ornithine may be substituted for lysine. The inventive polypeptide of the present invention also include any polypeptide having one or more additions and/or deletions of residues, relative to the sequence of a polypeptide whose sequence is shown herein, so long as the requisite PTTG or PTTG-C biological activity is maintained.

In accordance with peptide-based embodiments of the inventive method of inhibiting neoplastic cellular proliferation and/or transformation, the composition comprising the PTTG-C peptide is delivered to the cell. A suitable amount of the inventive PTTG-C peptide to be delivered to the cells, in accordance with the method, preferably ranges from about 0.1 nanograms to about 1 milligram per gram of tumor tissue, in vivo, or about 0.1 nanograms to about 1 microgram per 5000 cells, in vitro. Suitable amounts for particular varieties of PTTG-C peptide and/or cell types and/or for various individual mammalian subjects undergoing treatment, can be determined by routine experimentation.

Methods of delivering and importing peptides into target cells are known. For example, the composition preferably, but not necessarily, comprises in addition to the PTTG-C peptide, a complex in which the PTTG-C peptide is complexed with a cellular uptake-enhancing agent. For example, the PTTG-C peptide can be covalently linked in a complex to a cellular uptake-enhancing and/or importation-competent peptide segment for delivery of PTTG-C into the mammalian cell; in addition, a nuclear localization peptide can be included in the complex to direct the PTTG-C to the nucleus. (E.g., Lin *et al.*, *Method for importing biologically active molecules into cells*, U.S. Patent No. 6,043,339). An "importation-competent peptide," as used

herein, is a sequence of amino acids generally of a length of about 10 to about 50 or more amino acid residues, many (typically about 55-60%) residues of which are hydrophobic such that they have a hydrophobic, lipid-soluble portion. The hydrophobic portion is a common, major motif of a signal peptide, and it is often recognizable as a central part of the signal peptide of a protein
5 secreted from cells. A signal peptide is a peptide capable of penetrating through the cell membrane to allow the export of cellular proteins. Signal peptides useful in the present method are also "importation-competent," i.e., capable of penetrating through the cell membrane from outside the cell to the interior of the cell.

In a preferred embodiment, a PTTG-C peptide forms first PTTG-C peptide segment of
10 a chimeric or fusion protein. The chimeric or fusion protein comprises at least the first PTTG-C peptide segment and a second cellular uptake-enhancing and/or importation-competent peptide segment. The second segment of the chimeric or fusion protein is a cellular uptake-enhancing and/or importation-competent peptide segment, such as a signal peptide, that allows the hybrid molecule to enter neoplastic cells that overexpress PTTG, whether in vitro or in vivo. The
15 second peptide segment, such as the human immunodeficiency virus (HIV) TAT protein (Schwarze, S.R., *et al.*, *In vivo protein transduction: delivery of a biologically active protein into the mouse*, Science 285:1569-72 [1999]), infiltrates the cells, and once within the cells, the PTTG-C peptide segment of the fusion protein becomes active within the cells to inhibit endogenous *PTTG* expression and/or PTTG function. Another example of a useful uptake-
20 enhancing peptide segment is the signal peptide from Kaposi fibroblast growth factor (K-FGF). But any cellular uptake-enhancing and/or importation-competent peptide segment, capable of translocating across the cell membrane into the interior of the selected target mammalian cell, can be used according to this invention. The chimeric or fusion protein can also include additional segments, such as a linker segment, that can be an intervening segment between the first and
25 second segments. The additional segment can alternatively be a terminal segment, as appropriate.

In embodiments of the method involving the use of PTTG-C chimeric or fusion proteins, the cellular uptake-enhancing and/or importation-competent peptide segment can be the uptake-enhancing agent. Alternatively, or in addition, the cellular uptake-enhancing agent can be a lipid
30 or liposome uptake-enhancing agent as described herein above, such as lipofectin, lipofectamine,

DOTAP, and others. Cationic (or polycationic) lipids or liposomes can also be complexed with a signal peptide and a negatively-charged biologically active molecule by mixing these components and allowing them to charge-associate. Anionic liposomes generally are utilized to encapsulate within the liposome the substances to be delivered to the cell. Procedures for forming cationic liposome- encapsulating substances are standard in the art and can readily be utilized herein by one of ordinary skill in the art to encapsulate the complex of this invention. For example, liposome uptake-enhancing agents complexed with inventive PTTG-C peptide fragments can be encapsulated in polyethylene glycol (PEG), FuGENE6, or the like.

With respect to delivery of the composition to mammalian cells in vivo, the composition is administered to a mammalian subject in need of treatment, including a human subject, by any conventional delivery route. Preferably, the PTTG-C peptide, whether or not complexed with cellular uptake-enhancing and/or importation-competent peptides (e.g., signal or localization peptides), is injected intravenously, intra-arterially, intraperitoneally, or by means of injection directly into a tumor or into a cell by microinjection. Conventional stereotactic methods can be useful for direct injection into tumors or cells. In other preferred embodiments, controlled release formulations of biodegradable polymeric microspheres or nanospheres (e.g., polylactide-co-glycolide; PLGA) encapsulating the PTTG-C peptide, or PTTG-C chimeric or fusion protein are administered to the mammalian subject orally. (E.g., Zhu, G. et al., *Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide)*, Nature Biotechnology 18:52-57 [2000]). Administration by nasal, rectal, or vaginal delivery routes can also be useful. Administration by catheter or stent can also be useful for delivering the PTTG-C peptide.

In some embodiments, isolated and crystallized PTTG-C peptide can be cross-linked with a multifunctional crosslinking agent that inhibits proteolysis of the PTTG-C peptide in vivo. (Navia, M.A., *Method of protein therapy by orally administering crosslinked protein crystals*, U.S. Patent No. 6,011,001).

In accordance with the inventive method of inhibiting neoplastic cellular proliferation and/or transformation that is mediated by PTTG, the mammalian cell is a cell that overexpresses *PTTG*, the gene that encodes a PTTG protein. Although detecting *PTTG* overexpression by the cell is not essential or necessary to the practice of the inventive method, the level of *PTTG* expression, including overexpression, is detectable by one skilled in the art. Detection of *PTTG*

expression is accomplished by immunochemical assay for PTTG protein, for example, using the inventive anti-PTTG-C antibodies, described herein, or other anti-PTTG-specific antibodies. Alternatively, amplification of *PTTG*-specific mRNAs present in biological samples (e.g., tissue biopsy) can be used to detect *PTTG* expression. This is done by known molecular biological techniques of amplification and analysis of the amplification products for the presence or absence of *PTTG*-specific amplification products. If *PTTG* gene-specific amplification products are present, the findings are indicative of expression of the *PTTG* gene and diagnostic of the presence of neoplastic cellular proliferation in the subject as defined herein.

However, for interpretation of negatives (no *PTTG*-specific amplification products) analysis is preferably carried out following a control amplification of nucleic acids specific for a housekeeping gene, for example, a gene encoding β -actin, phosphofructokinase (PFK), glyceraldehyde 3-phosphate dehydrogenase, or phosphoglycerate kinase. Only if expression of the housekeeping gene is detected in the sample, is the absence of *PTTG* gene expression reliably accepted. With increasing sensitivity of amplification and analysis methods employed, it becomes increasingly preferable to determine the level of *PTTG* gene expression relative to expression of a housekeeping gene, in order to better distinguish neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation from the detectable background of normal cellular division. The ratio of *PTTG* expression to housekeeping gene expression is determined, for example, by real-time PCR methods or densitometric measurement and analysis of electrophoretic bands after amplification. When the ratio of *PTTG* expression to housekeeping gene expression exceeds a normal cell standard range and/or approximates an abnormal (e.g., neoplastic) cell standard range, this indicates overexpression of *PTTG* gene product, characteristic of neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation.

PTTG-specific mRNAs in a biological sample are amplified by a suitable amplification method. For example, a reverse transcriptase-mediated polymerase chain reaction (RT-PCR) is employed to amplify *PTTG*-specific nucleic acids. Briefly, two enzymes are used in the amplification process, a reverse transcriptase to transcribe *PTTG*-specific cDNA from a *PTTG*-specific mRNA template in the sample, a thermal resistant DNA polymerase (e.g., *Taq* polymerase), and *PTTG*-specific primers to amplify the cDNA to produce *PTTG* gene-specific

amplification products. The use of limited cycle PCR yields semi-quantitative results. (E.g., Gelfand *et al.*, *Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription*, U.S. Patent Nos. 5,310,652; 5,322,770; Gelfand *et al.*, *Unconventional nucleotide substitution in temperature selective RT-PCR*, U.S. Patent No. 5,618,703).

5 Alternatively, single enzyme RT-PCR is employed to amplify *PTTG* gene-specific nucleic acids. Single enzymes now exist to perform both reverse transcription and polymerase functions, in a single reaction. For example, the Perkin Elmer recombinant *Thermus thermophilus* (rTth) enzyme (Roche Molecular), or other similar enzymes, are commercially available.

Real-time RT-PCR can be employed to amplify *PTTG*-specific nucleic acids. Briefly, this
10 is a quantitative gene analysis based on the ratio of *PTTG* gene expression and the expression of a housekeeping gene, i.e., a gene that is expressed at about the same level in normal and abnormal (e.g., malignant) cells, for example, a gene encoding β -actin, phosphofructokinase, glyceraldehyde 3-phosphate dehydrogenase, or phosphoglyceratekinase. The the ratio of the *PTTG* and housekeeping genes' expressions is routinely established as a standard for normal and abnormal
15 cells, which standard expression ratio(s) is (are) used for comparison in determining that expression of the *PTTG* gene relative to expression of the "housekeeping" gene in a given sample is either "normal" or "increased", the latter indicative of "overexpression" and diagnostic for the presence of neoplastic, hyperplastic, cytologically dysplastic and/or premalignant cellular growth or proliferation. In this embodiment, the ratio is the key to diagnosis and constitutes quantitative
20 gene expression analysis. This embodiment utilizes so-called real-time quantitative PCR, carried out with commercially available instruments, such as the Perkin Elmer ABI Prism 7700, the so-called Light Cycler (Roche Molecular), and/or other similar instruments. Optionally, single enzyme RT-PCR technology, for example, employing rTth enzyme, can be used in a real-time PCR system. Preferably, amplification and analysis are carried out in an automated fashion, with
25 automated extraction of mRNA from a urine sediment sample, followed by real-time PCR, and fluorescence detection of amplification products using probes, such as TaqMan or Molecular Beacon probes. Typically, the instrumentation includes software that provides quantitative analytical results during or directly following PCR without further amplification or analytical steps.

30 Alternatively, transcription-mediated amplification (TMA) is employed to amplify *PTTG*

gene-specific nucleic acids. (E.g., K. Kamisango *et al.*, *Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay*, J. Clin. Microbiol. 37(2):310-14 [1999]; M. Hirose *et al.*, *New method to measure telomerase activity by transcription-mediated amplification and hybridization protection assay*, Clin. Chem. 44(12):2446-52 [1998]). Rather than employing RT-PCR for the amplification of a cDNA, TMA uses a probe that recognizes a *PTTG*-specific (target sequence) RNA; in subsequent steps, from a promoter sequence built into the probe, an RNA polymerase repetitively transcribes a cDNA intermediate, in effect amplifying the original RNA transcripts and any new copies created, for a level of sensitivity approaching that of RT-PCR. The reaction takes place isothermally (one temperature), rather than cycling through different temperatures as in PCR.

Other useful amplification methods include a reverse transcriptase-mediated ligase chain reaction (RT-LCR), which has utility similar to RT-PCR. RT-LCR relies on reverse transcriptase to generate cDNA from mRNA, then DNA ligase to join adjacent synthetic oligonucleotides after they have bound the target cDNA.

Amplification of a *PTTG* gene-specific nucleic acid segment of the subject can be achieved using *PTTG* gene-specific oligonucleotide primers and primer sets as provided herein.

Optionally, high throughput analysis may be achieved by PCR multiplexing techniques well known in the art, employing multiple primer sets, for example primers directed not only to *PTTG* gene-specific nucleic acids, but to amplifying expression products of housekeeping genes (controls) or of other potential diagnostic markers (e.g., oncogenes), as well, such as MAG or telomerase, to yield additional diagnostic information. (E.g., Z. Lin *et al.*, *Multiplex genotype determination at a large number of gene loci*, Proc. Natl. Acad. Sci. USA 93(6):2582-87 [1996]; Demetriou *et al.*, *Method and probe for detection of gene associated with liver neoplastic disease*, U.S. Patent No. 5,866,329).

Hybridization analysis is a preferred method of analyzing the amplification products, employing one or more *PTTG*-specific probe(s) that, under suitable conditions of stringency, hybridize(s) with single stranded *PTTG*-specific nucleic acid amplification products comprising complementary nucleotide sequences. Hybridization refers to the binding of complementary strands of nucleic acid (i.e., sense:antisense strands or probe:target-DNA) to each other through hydrogen bonds, similar to the bonds that naturally occur in chromosomal DNA. The

amplification products are typically deposited on a substrate, such as a cellulose or nitrocellulose membrane, and then hybridized with labeled *PTTG*-specific probe(s), optionally after an electrophoresis. Conventional dot blot, Southern, Northern, or fluorescence in situ (FISH) hybridization protocols, *in liquid* hybridization, hybridization protection assays, or other semi-quantitative or quantitative hybridization analysis methods are usefully employed along with the *PTTG* gene-specific probes of the present invention. Preferred probe-based hybridization conditions comprise a temperature of about 37°C, a formamide concentration of about 20%, and a salt concentration of about 5X standard saline citrate (SSC; 20 x SSC contains 3 M sodium chloride, 0.3 M sodium citrate, pH 7.0). Such conditions will allow the identification of sequences which have a substantial degree of similarity with the probe sequence, without requiring perfect homology. The phrase "substantial similarity" refers to sequences which share at least 50% homology. Stringency levels used to hybridize a given probe with target-DNA can be readily varied by those of skill in the art. Preferably, hybridization conditions will be selected which allow the identification of sequences having at least about 60% homology with the probe, while discriminating against sequences which have a lower degree of homology with the probe.

As used herein, a "probe" is single-stranded DNA or RNA, or a nucleic acid analog. The inventive probe is preferably 7 to 500 nucleotides long, more preferably 14 to 150 nucleotides long, and most preferably at least 50 nucleotides long. The probe comprises, for at least part of its length, a *PTTG*-specific nucleotide sequence at least 7 to 15 contiguous nucleotides long, such that the probe hybridizes to a *PTTG*-specific single stranded nucleic acid under suitably stringent hybridization conditions. Examples of *PTTG*-specific nucleotide sequences are set forth in any of SEQ. ID. NOS.: 1, 3, 10, 15, 18, or 19, preferably, but not necessarily, including 5' and/or 3' coding regions thereof. In addition, the entire cDNA encoding region of an inventive *PTTG*-specific nucleotide sequence, or the entire sequence corresponding to SEQ. ID. NOS.: 1, 3, 10, 15, 18, 19, or nucleotide sequences complementary to any of these, can be used as a probe. For example, probes comprising inventive oligonucleotide primer sequences, such as, but not limited to, SEQ. ID. NO.:8, can be labeled for use as probes for detecting or analyzing *PTTG*-specific nucleic acid amplification products. Any of the inventive isolated *PTTG*-C-related polynucleotides can be used as probes or primers.

Alternatively, electrophoresis for analyzing amplification products is done rapidly and with high sensitivity by using any of various methods of conventional slab or capillary electrophoresis, with which the practitioner can optionally choose to employ any facilitating means of nucleic acid fragment detection, including, but not limited to, radionuclides, UV-absorbance or laser-induced fluorescence. (K. Keparnik *et al.*, *Fast detection of a (CA)18 microsatellite repeat in the IgE receptor gene by capillary electrophoresis with laser-induced fluorescence detection*, Electrophoresis 19(2):249-55 [1998]; H. Inoue *et al.*, *Enhanced separation of DNA sequencing products by capillary electrophoresis using a stepwise gradient of electric field strength*, J. Chromatogr. A. 802(1):179-84 [1998]; N.J. Dovichi, *DNA sequencing by capillary electrophoresis*, Electrophoresis 18(12-13):2393-99 [1997]; H. Arakawa *et al.*, *Analysis of single-strand conformation polymorphisms by capillary electrophoresis with laser induced fluorescence detection*, J. Pharm. Biomed. Anal. 15(9-10):1537-44 [1997]; Y. Baba, *Analysis of disease-causing genes and DNA-based drugs by capillary electrophoresis. Towards DNA diagnosis and gene therapy for human diseases*, J. Chromatogr B. Biomed. Appl. 687(2):271-302 [1996]; K.C. Chan *et al.*, *High-speed electrophoretic separation of DNA fragments using a short capillary*, J. Chromatogr B. Biomed. Sci. Appl. 695(1):13-15 [1997]). Probes can be labeled by methods well-known in the art.

As used herein, the terms "label", "tracer", and "indicating means" in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal. Any label or indicating means can be linked to PTTG-specific probes, primers, or amplification products, or PTTG proteins, peptides, peptide fragments, or anti-PTTG antibody molecules. The label can be used alone or in conjunction with additional reagents. Such labels are themselves well-known in the art. The label can be a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturation to form a fluorochrome (dye) that is a useful immunofluorescent tracer. A description of immunofluorescent analytic techniques is found in DeLuca, "Immunofluorescence Analysis", in Antibody As a Tool, Marchalonis *et al.*, eds., John Wiley & Sons, Ltd., pp. 189-231 (1982), which is incorporated herein by reference. Any of diverse fluorescent dyes can optionally be used as a label, including but not limited to, SYBR Green I, Y1O-PRO-1, thiazole orange, Hex (i.e., 6-carboxy-2',4',7',4,7-hexachlorofluoroscein), pico green, edans, fluorescein, FAM (i.e., 6-

carboxyfluorescein), or TET (i.e., 4,7,2',7'-tetrachloro-6-carboxyfluorescein). (E.g., J. Skeidsvoll and P.M. Ueland, *Analysis of double-stranded DNA by capillary electrophoresis with laser-induced fluorescence detection using the monomeric dye SYBR green I*, Anal. Biochem. 231(20):359-65 [1995]; H. Iwahana *et al.*, *Multiple fluorescence-based PCR-SSCP analysis using internal fluorescent labeling of PCR products*, Biotechniques 21(30):510-14, 516-19 [1996]).

The label can also be an enzyme, such as horseradish peroxidase (HRP), glucose oxidase, β -galactosidase, and the like. Alternatively, radionuclides are employed as labels. The linking of a label to a substrate, i.e., labeling of nucleic acid probes, antibodies, polypeptide, and proteins, is well known in the art. For instance, an invention antibody can be labeled by metabolic incorporation of radiolabeled amino acids provided in the culture medium. See, for example, Galfre *et al.*, Meth. Enzymol., 73:3-46 (1981). Conventional means of protein conjugation or coupling by activated functional groups are particularly applicable. See, for example, Aurameas *et al.*, Scand. J. Immunol., Vol. 8, Suppl. 7:7-23 (1978), Rodwell *et al.*, Biotech., 3:889-894 (1984), and U.S. Patent No. 4,493,795.

In accordance with yet another embodiment of the present invention, there are provided anti-PTTG antibodies having specific reactivity with PTTG polypeptides of the present invention. Antibody fragments, for example Fab, Fab', F(ab')₂, or F(v) fragments, that selectively or specifically bind a PTTG protein, PTTG-C peptide, or immunogenic fragment of PTTG-C, are also encompassed within the definition of "antibody".

Inventive antibodies can be produced by methods known in the art using PTTG polypeptide, proteins or portions thereof, such as PTTG-C peptide or immunogenic fragments of PTTG-C, as antigens. For example, polyclonal and monoclonal antibodies can be produced by methods well known in the art, as described, for example, in Harlow and Lane, *Antibodies: A Laboratory Manual* (Cold Spring Harbor Laboratory [1988]), which is incorporated herein by reference. Isolated or purified PTTG proteins, PTTG-C peptides, and immunogenic PTTG-C fragments can be used as immunogens in generating such specific antibodies.

PTTG proteins, PTTG-C peptides, or polypeptide analogs thereof, are purified or isolated by a variety of known biochemical means, including, for example, by the recombinant expression systems described herein, precipitation, gel filtration, ion-exchange, reverse-phase and

affinity chromatography, and the like. Other well-known methods are described in Deutscher *et al.*, *Guide to Protein Purification: Methods in Enzymology* Vol. 182, (Academic Press, [1990]), which is incorporated herein by reference. Isolated PTTG proteins or PTTG-C peptides are free of cellular components and/or contaminants normally associated with a native in vivo environment.

Isolated PTTG proteins or PTTG-C peptides can also be chemically synthesized. For example, synthetic polypeptide can be produced using Applied Biosystems, Inc. Model 430A or 431A automatic peptide synthesizer (Foster City, CA) employing the chemistry provided by the manufacturer. Alternatively, PTTG can be isolated or purified from native sources, and PTTG-C peptides can be isolated from PTTG (or from chimeric proteins) by the use of suitable proteases.

Alternatively, PTTG or PTTG-C polypeptides can be recombinantly derived, for example, produced by mammalian cells genetically modified to express PTTG-C-encoding polynucleotides in accordance with the inventive technology as described herein. Recombinant methods are well known, as described, for example, in Sambrook et al., *supra.*, 1989). An example of the means for preparing the inventive PTTG or PTTG-C polypeptide(s) is to express nucleic acids encoding the PTTG protein or PTTG-C peptide in a suitable host cell, such as a bacterial cell, a yeast cell, an amphibian cell (i.e., oocyte), or a mammalian cell, such as the inventive mammalian host cell described herein below, using methods well known in the art, and recovering the expressed polypeptide, again using well-known methods.

The Immunogenicity of various PTTG-C fragments of interest is determined by routine screening. Alternatively, synthetic PTTG or PTTG-C polypeptides or fragments thereof can be prepared (using commercially available synthesizers) and used as immunogens. Amino acid sequences can be analyzed by methods well known in the art to determine whether they encode hydrophobic or hydrophilic domains of the corresponding polypeptide. Altered antibodies such as chimeric, humanized, CDR-grafted or bifunctional antibodies can also be produced by methods well known in the art. Such antibodies can also be produced by hybridoma, chemical synthesis or recombinant methods described, for example, in Sambrook et al., *supra.*, and Harlow and Lane, *supra.* Both anti-peptide and anti-fusion protein antibodies can be used. (see, for example, Bahouth et al., *Trends Pharmacol. Sci.* 12:338 [1991]; Ausubel et al., *Current Protocols in*

Molecular Biology (John Wiley and Sons, NY [1989] which are incorporated herein by reference).

Antibody so produced can be used, *inter alia*, in diagnostic or assay methods and systems to detect the level of PTTG protein, PTTG-C peptide, or immunogenic fragments thereof, present in a mammalian, preferably human, biological sample, such as tissue or vascular fluid. This is useful, for example, in determining the level of PTTG expression. Such antibodies can also be used for the immunoaffinity or affinity chromatography purification of the inventive PTTG proteins or PTTG-C peptides. In addition, methods are contemplated herein for detecting the presence of PTTG protein or PTTG-C peptide, either on the surface of a cell or within a cell (such as within the nucleus), which methods comprise contacting the cell with an antibody that specifically binds to PTTG protein or PTTG-C peptide, under conditions permitting specific binding of the antibody to PTTG protein or PTTG-C peptide, detecting the presence of the antibody bound to PTTG or PTTG-C, and thereby detecting the presence of PTTG or PTTG-C polypeptide on the surface of, or within, the cell. With respect to the detection of such polypeptide, the antibodies can be used for *in vitro* diagnostic or assay methods, or *in vivo* imaging methods.

Immunological procedures useful for *in vitro* detection of target PTTG or PTTG-C polypeptides in a sample include immunoassays that employ a detectable antibody. Such immunoassays include, for example, ELISA, immunofluorescence assay (IFA), Pandex microfluorimetric assay, agglutination assays, flow cytometry, serum diagnostic assays and immunohistochemical staining procedures which are well known in the art. An antibody can be made detectable by various means well known in the art. For example, a detectable marker can be directly or indirectly attached to the antibody. Useful markers include, for example, radionuclides, enzymes, fluorogens, chromogens and chemiluminescent labels.

Inventive anti-PTTG or anti-PTTG-C antibodies are also contemplated for use herein to modulate activity of the PTTG polypeptide in living animals, in humans, or in biological tissues or fluids isolated therefrom. Accordingly, compositions comprising a carrier and an amount of an antibody having specificity for PTTG polypeptide effective to block naturally occurring ligands or other PTTG-binding proteins from binding to invention PTTG polypeptide are contemplated herein. For example, a monoclonal antibody directed to an epitope of PTTG polypeptide

molecules present on the surface of a cell and having an amino acid sequence substantially the same as an amino acid sequence for a cell surface epitope of an PTTG polypeptide including the amino acid sequence shown in SEQ ID NOS:2, 4, 9, 14, 16, or 17 can be useful for this purpose.

The present invention also relates to transfected, transduced, or otherwise transformed
5 mammalian host cells, including lymphocyte and non-lymphocyte cells, comprising any of the inventive PTTG-C-related polynucleotide-containing compositions as described herein above. The inventive cells are either contained in a mammalian subject or are cultured in vitro. Included among preferred embodiments are mammalian host cells containing an expression vector comprising the inventive PTTG-C-related polynucleotide in a transcriptional unit. Preferably,
10 a product is expressed by the cell, which product, most preferably, but not necessarily, is a biologically active PTTG-C peptide that functions to downregulate PTTG-mediated neoplastic cellular proliferation and/or transformation. In vitro and in vivo methods of transfecting, transducing, or transforming suitable host cells are generally known in the art. Methods for culturing cells, in vitro, are also well known. Exemplary methods of transfection, transduction,
15 or transformation include, e.g., infection employing viral vectors (see, e.g., U.S. Patent 4,405,712 and 4,650,764), calcium phosphate transfection (U.S. Patents 4,399,216 and 4,634,665), dextran sulfate transfection, electroporation, lipofection (see, e.g., U.S. Patents 4,394,448 and 4,619,794), cytofection, microparticle bombardment, and the like. The heterologous nucleic acid can optionally include sequences which allow for its extrachromosomal (i.e., episomal)
20 maintenance, or heterologous DNA can be caused to integrate into the genome of the host (as an alternative means to ensure stable maintenance in the host cell).

The present invention further provides transgenic non-human mammals containing the inventive mammalian cells that are capable of expressing exogenous nucleic acids encoding PTTG polypeptides, particularly the inventive PTTG-C peptides and functional fragments thereof as
25 described hereinabove. As employed herein, the phrase "exogenous nucleic acid" refers to nucleic acid sequence which is not native to the host, or which is present in the host in other than its native environment (e.g., as part of a genetically engineered DNA construct). Methods of producing transgenic non-human mammals are known in the art. Typically, the pronuclei of fertilized eggs are microinjected in vitro with foreign, i.e., xenogeneic or allogeneic DNA or
30 hybrid DNA molecules, and the microinjected fertilized eggs are then transferred to the genital

tract of a pseudopregnant female to gestate to term. (E.g., P.J.A. Krimpenfort *et al.*, *Transgenic mice depleted in mature T-cells and methods for making transgenic mice*, U.S. Pat. Nos. 5,175,384 and 5,434,340; P.J.A. Krimpenfort *et al.*, *Transgenic mice depleted in mature lymphocytic cell-type*, U.S. Pat. No. 5,591,669). Alternatively, methods for producing
5 transgenic non-human mammals can involve genetic modification of female or male germ cells using an expression vector, which germ cells are then used to produce zygotes, which are gestated to term. The resulting offspring are selected for the desired phenotype. These offspring can further be bred or cloned to produce additional generations of transgenic animals with the desired phenotype. The inventive transgenic non-human mammals, preferably, but not
10 necessarily, are large animals such as bovines, ovines, porcines, equines, and the like, that produce relatively large quantities of PTTG-C peptides that can be harvested for use in practicing the method of inhibiting neoplastic cellular proliferation and/or transformation.

Most preferably, the transgenic non-human mammal is a female that produces milk into which the inventive PTTG-C peptides have been secreted. The PTTG-C peptides are then
15 purified from the milk. (E.g., Christa, L., *et al.*, *High expression of the human hepatocarcinoma-intestine-pancreas/pancreatic-associated protein (HIPAP) gene in the mammary gland of lactating transgenic mice secretion into the milk and purification of the HIP/PAP lectin*, Eur. J. Biochem. 267(6):1665-71 [2000]; Sobolev, A.S. *et al.*, *Receptor-mediated transfection of murine and ovine mammary glands in vivo*, J. Biol. Chem.
20 273(14):7928-33 [1998]; Zhang, K. *et al.*, *Construction of mammary gland-specific expression vectors for human clotting factor IX and its secretory expression in goat milk*, Chin. J. Biotechnol. 13(4):271-6 [1997]; Clark, A.J., *Gene expression in the mammary glands of transgenic animals*, Biochem. Soc. Symp. 63:133-40 [1998]; Niemann, H. *et al.*, *Expression of human blood clotting factor VIII in the mammary gland of transgenic sheep*, Transgenic Res.
25 8(3):237-47 [1999]).

Techniques for obtaining the preferred transgenic female mammals typically employ transfection with an expression vector in which, within a transcriptional unit regulated, for example, by a suitable β -lactoglobulin promoter, the PTTG-C peptide-encoding polynucleotide is chimerically linked with a polynucleotide encoding a mammary secretory signal peptide, such
30 that mammary-specific expression yields a chimeric polypeptide from which the desired PTTG-C

peptide segment is removed proteolytically and purified.

The present invention is also directed to a kit for the treatment of neoplastic cellular proliferation. The kit is useful for practicing the inventive method of inhibiting neoplastic cellular proliferation and/or transformation. The kit is an assemblage of materials or components, including at least one of the inventive compositions containing a PTTG-C-related polynucleotide and/or PTTG-C peptides, as described above. The exact nature of the components configured in the inventive kit depends on its intended purpose. For example, some embodiments of the kit are configured for the purpose of treating cultured mammalian cells. Other embodiments are configured for the purpose of treating mammalian cells in vivo, i.e., for treating mammalian subjects in need of treatment, for example, subjects with malignant tumors. In a most preferred embodiment, the kit is configured particularly for the purpose of treating human subjects.

Some embodiments of the kit include a kit for the treatment of neoplastic cellular proliferation of T-lymphocytes, which includes a composition comprising a tamed HIV vector operatively linked to a PTTG carboxy-terminal-related polynucleotide; and instructions for the use of said composition for inhibiting neoplastic cellular proliferation and/or transformation of T-lymphocytes.

Also included within the present invention is a kit for immunosuppressive therapy, which contains a composition comprising a tamed HIV vector operatively linked to a PTTG carboxy-terminal-related polynucleotide; and instructions for using the composition for inhibiting the activation of T-lymphocytes.

Instructions for use are included in the kit. "Instructions for use" typically include a tangible expression describing the reagent concentration or at least one assay method parameter, such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions, and the like, typically for an intended purpose.

Optionally, the kit also contains other useful components, such as, diluents, buffers, pharmaceutically acceptable carriers, specimen containers, syringes, stents, catheters, pipetting or measuring tools, paraphernalia for concentrating, sedimenting, or fractionating samples, or the inventive antibodies, and/or primers and/or probes for controls.

The materials or components assembled in the kit can be provided to the practitioner

stored in any convenient and suitable ways that preserve their operability and utility. For example the components can be in dissolved, dehydrated, or lyophilized form; they can be provided at room, refrigerated or frozen temperatures.

5 The components are typically contained in suitable packaging material(s). As employed herein, the phrase "packaging material" refers to one or more physical structures used to house the contents of the kit, such as invention nucleic acid probes or primers, and the like. The packaging material is constructed by well known methods, preferably to provide a sterile, contaminant-free environment.

10 The packaging materials employed in the kit are those customarily utilized in polynucleotide-based or peptide-based systems. As used herein, the term "package" refers to a suitable solid matrix or material such as glass, plastic, paper, foil, and the like, capable of holding the individual kit components. Thus, for example, a package can be a glass vial used to contain suitable quantities of an inventive composition containing nucleic acid or peptide components. The packaging material generally has an external label which indicates the contents and/or
15 purpose of the kit and/or its components.

**The invention also relates to a screening substances for new immunosuppressive agents. The method involves culturing lymphocytes; exposing the cultured lymphocytes to a potential immunosuppressive agent in the presence of a known lymphocyte activator; and detecting a change in the expression level of PTTG in the lymphocytes compared to
20 control lymphocytes not exposed to the potential immunosuppressive agent, downregulation of PTTG expression being indicative of an immunosuppressive capacity possessed by the potential immunosuppressive agent.**

The invention will now be described in greater detail by reference to the following non-limiting examples, which unless otherwise stated were performed using standard procedures, as
25 described, for example in Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA (1982); Sambrook et al., Molecular Cloning: A Laboratory Manual (2 ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA (1989); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (1986); or Methods in Enzymology: Guide
30 to Molecular Cloning Techniques Vol.152, S. L. Berger and A. R. Kimmerl Eds., Academic Press

Inc., San Diego, USA (1987).

EXAMPLES

Example 1: Isolation of PTTG cDNA

To clarify the molecular mechanisms involved in pituitary tumorigenesis, differential display PCR was used to identify mRNAs differentially expressed in pituitary tumor cells (see, e.g., Risinger et al., 1994, Molec. Carcinogenesis, 11:13-18; and Qu et al., 1996, Nature, 380:243-247). GC and GH₄ pituitary tumor cell lines (ATCC #CCL-82 and #CCL-82.1, respectively) and an osteogenic sarcoma cell line UM108 (ATCC #CRL-1663) were grown in DMEM supplemented with 10% fetal bovine serum. Normal Sprague-Dawley rat pituitaries were freshly excised. Total RNA was extracted from tissue cultured cells and pituitary tissue using RNeasy™ kit (Qiagen) according to manufacturer's instructions. Trace DNA contamination in RNA preparations was removed by DNaseI (GenHunter Corporation) digestion. cDNA was synthesized from 200 ng total RNA using MMLV reverse transcriptase (GenHunter Corporation), and one of the three anchored primers (GenHunter Corporation). The cDNA generated was used in the PCR display.

Three downstream anchored primers AAGCT₁₁N (SEQ. ID. NO.:13; where N may be A, G, or C), were used in conjunction with 40 upstream arbitrary primers for PCR display. 120 primer pairs were used to screen mRNA expression in pituitary tumors versus normal pituitary. One tenth of the cDNA generated from the reverse transcriptase reaction was amplified using AmpliTaq DNA polymerase (Perkin Elmer) in a total volume of 20 µl containing 10 mM Tris, pH 8.4, 50 mM KCl, 1.5 mM MgCl₂, 0.001% gelatin, 2 µM dNTPs, 0.2 µM each primer and 1 µl [³⁵S]dATP. PCR cycles consisted of 30 seconds at 94°C, 2 minutes at 40°C, and 30 seconds at 72°C for 40 cycles. The products were separated on 6% sequencing gels, and dried gels were exposed to Kodak film for 24 to 48 hours.

After development, DNA fragments amplified from pituitary tumor and normal pituitary were compared. Bands unique to pituitary tumor were excised from the gel, and DNA extracted by boiling in 100 µl water and precipitated with ethanol in the presence of glycogen (GenHunter Corporation). DNA was reamplified using the original set of primers and the same thermal cycling conditions except that the dNTP concentration was increased to 20 µM. Reaction

products were run on 1% agarose gel and stained with ethidium bromide. Bands were excised from the gel, eluted (Qiagen), cloned in to TA vectors (Invitrogen) and sequenced using sequenase (USB). Using 120 primer pairs in the above-described PCR assay, 11 DNA bands that appeared to be differentially expressed in pituitary tumor cells were identified. These bands were
5 evaluated further by Northern blot analysis, using the PCR products as probes.

For Northern blot analysis, 20 µg of total RNA were fractionated on 1% agarose gel, blotted on to nylon membrane and hybridized with random primed probe using Quickhyb solutions (Stratagene). After washing, membranes were exposed to Kodak films for 6 to 72 hours. As a result of the Northern blot assay, pituitary tumor specific signals were detected for
10 2 bands. DNA sequence analysis revealed that one sequence was homologous with Insulin-induced growth response protein, while the another 396 base pair fragment (amplified using 5'-AAGCTTTTTTTTTTTTG-3' [SEQ. ID. NO.:11] as the anchored primer and 5'-AAGCTTGCTGCTC-3' [SEQ. ID. NO.:12] as an arbitrary primer) showed no homology to known sequences in the GenBank. This 396 bp fragment detected a highly expressed mRNA of
15 about 1.3 kb in pituitary tumor cells, but not in normal pituitary nor in osteogenic sarcoma cells.

Example 2: Characterization of cDNA sequence encoding PTTG.

To characterize this pituitary tumor-specific mRNA further, a cDNA library was constructed using mRNA isolated from rat pituitary tumor cells. Poly A+RNA was isolated from pituitary tumor GH₄ cells using messenger RNA isolation kit (Stratagene) according to
20 manufacturer's instructions, and was used to construct a cDNA library in ZAP Express vectors (Stratagene). The cDNA library was constructed using ZAP Express™ cDNA synthesis and Gigapack III gold cloning kit (Stratagene) following manufacturer's instructions. The library was screened using the 396 bp differentially displayed PCR product (cloned into TA vector) as the probe. After tertiary screening, positive clones were excised by *in vivo* excision using helper
25 phage. The resulting pBK-CMV phagemid containing the insert was identified by Southern Blotting analysis. Unidirectional nested deletions were made into the DNA insert using EXOIII/Mung bean nuclease deletion kit (Stratagene) following manufacturer's instructions. Both strands of the insert DNA were sequenced using Sequenase (USB).

Using the 396 bp PCR fragment described in Example 1 as a probe, a cDNA clone of 974 bp (SEQ. ID. NO.:1) was isolated and characterized. This cDNA was designated as pituitary tumor-specific gene (*PTTG*). The sequence of *PTTG* contains an open reading frame for 199 amino acids (SEQ ID NO:2). The presence of an in-frame stop codon upstream of the predicted initiation codon indicates that *PTTG* contains the complete ORF. This was verified by demonstrating both *in vitro* transcription and *in vitro* translation of the gene product as described in Example 3.

Example 3: In vitro Transcription and translation of the PTTG

Sense and antisense *PTTG* mRNAs were *in vitro* transcribed using T3 and T7 RNA polymerase (Stratagene), respectively. The excess template was removed by DNase I digestion. The *in vitro* transcribed mRNA was translated in rabbit reticular lysate (Stratagene). Reactions were carried out at 30°C for 60 minutes, in a total volume of 25 µl containing 3 µl *in vitro* transcribed RNA, 2 µl ³⁵S-Methionine (Dupond) and 20 µl lysate. Translation products were analyzed by SDS-PAGE (15% resolving gel and 5% stacking gel), and exposed to Kodak film for 16 hours.

The results indicate that translation of *in vitro* transcribed *PTTG* sense mRNA results in a protein of approximately 25 KD on SDS-PAGE, whereas no protein was generated in either the reaction without added mRNA or when *PTTG* antisense mRNA was utilized.

Example 4: Northern Blot Analysis of PTTG mRNA expression

A search of GenBank and a protein profile analysis (using a BLAST Program search of databases of the national center for Biotechnology Information) indicated that *PTTG* shares no homology with known sequences, and its encoded protein is highly hydrophilic, and contains no well recognized functional motifs. The tissue expression pattern of *PTTG* mRNA was studied by Northern Blot analysis. A rat multiple tissue Northern blot was purchased from Clontech. Approximately 2 µg of poly A+ RNA per lane from eight different rat tissues (heart, brain, spleen, lung, liver, skeletal muscle, kidney, and testis) was run on a denaturing formaldehyde 1.2% agarose gel, transferred to nylon membrane and UV-cross linked. The membrane was first hybridized to the full length *PTTG* cDNA probe, and was stripped and rehybridized to a human

β -actin cDNA control probe. Hybridization was performed at 60°C for one hour in ExpressHyb hybridization solution (Clontech). Washing was twice 15 minutes at room temperature in 2xSSC, 0.05%SDS, and twice 15 minutes at 50°C in 0.1%SSC, 0.1%SDS. Exposure time for *PTTG* probe was 24 hrs, and actin probe 2 hours.

- 5 The results of the Northern assay indicate that testis is the only tissue, other than pituitary tumor cells, that expresses *PTTG* mRNA, and the testis expression level is much lower (2 μ g polyA+ mRNA, 24 hour exposure) than in pituitary tumor cells (20 μ g total RNA, 6 hour exposure). Interestingly, the testicular transcript (about 1 Kb) is shorter than the transcript in pituitary tumors (1.3 Kb), indicating that the mRNA is differentially spliced in testis, and that the
- 10 1.3 Kb transcript is specific for pituitary tumor cells.

Example 5: Over-expression of *PTTG* in NIH 3T3 fibroblast cells

- Since *PTTG* mRNA is over-expressed in pituitary tumor cells, whether this protein exerts an effect on cell proliferation and transformation was determined. An eukaryotic expression vector containing the entire coding region of *PTTG* was stably transfected into NIH 3T3
- 15 fibroblasts.

- The entire coding region of the *PTTG* was cloned in frame into pBK-CMV eukaryotic expression vector (Stratagene), and transfected into NIH 3T3 cells by calcium precipitation. 48 hrs after transfection, cells were diluted 1:10 and grown in selection medium containing 1 mg/ml G418 for two weeks in when individual clones were isolated. Cell extracts were prepared from
- 20 each colony and separated on 15% SDS-polyacrylamide gels, and blotted onto nylon membrane. A polyclonal antibody was generated using the first 17 amino acids of PTTG as epitope (Research Genetics). The antibody was diluted 1:5000 and incubated with the above membrane at room temperature for 1 hour. After washing, the membrane was incubated with horseradish peroxidase-labeled secondary antibody for one hour at room temperature. The hybridization
- 25 signal was detected by enhanced chemiluminescence (ECL detection system, Amersham).

 Expression levels of the PTTG were monitored by immunoblot analysis using the above-described specific polyclonal antibody directed against the first 17 amino acids of the protein. Expression levels of individual clones varied, and clones that expressed higher protein levels were used for further analysis.

Example 6: Effect of PTTG expression on cell proliferation

A non-radioactive cell proliferation assay was used to determine the effect of PTTG protein over-expression on cell proliferation (see, e.g., Mosmann, T., 1983, J. Immunol. Meth., 65:55-63; and Carmichael et al., 1987, Cancer Res., 47:943-946). Cell proliferation was assayed
5 using CellTiter 96TM Non-radioactive cell proliferation assay kit (Promega) according to the manufacturer's instructions. Five thousand cells were seeded in 96 well plates (6 wells for each clone in each assay), and incubated at 37°C for 24 to 72 hours. At each time point, 15 µl of the Dye solution were added to each well, and incubated at 37°C for 4 hours. One hundred µl of the solubilization/stop solution were then added to each well. After one hour incubation, the contents
10 of the wells were mixed, and absorbance at 595 nm was recorded using an ELISA reader. Absorbance at 595 nm correlates directly with the number of cells in each well.

Three independent experiments were performed. The cell growth rate of 3T3 cells expressing PTTG protein (assayed by cellular conversion of tetrazolium into formazan) was suppressed 25 to 50% as compared with 3T3 cells expressing the pCMV vector alone, indicating
15 that PTTG protein inhibits cell proliferation (data not shown).

Example 7: PTTG Induction of Morphological Transformation and Soft-agar Growth of NIH 3T3 Cells

The transforming property of PTTG protein was demonstrated by its ability to form foci in monolayer cultures and show anchorage-independent growth in soft agar (Table 1). As primary
20 pituitary cells are an admixture of multiple cell types and they do not replicate *in vitro*, NIH 3T3 cells were employed. For the soft agar assay (Schwab et al., 1985, Nature, 316:160-162), 60 mM tissue culture plates were coated with 5 ml soft-agar (20% 2x DEEM, 50% DEEM, 10% fetal bovine serum, 20% 2.5% agar, melted and combined at 45°C). 2 ml cells suspended in medium were then combined with 4 ml agar mixture, and 1.5 ml of this mixture added to each plate. Cells
25 were plated at a density of 10^4 cells/dish and incubated for 14 days before counting the number of colonies and photography. Only colonies consisting of at least 40 cells were counted. Values shown in Table 1 are means \pm SEM of triplicates.

Table 13: Colony Formation by NIH 3T3 Cells Transfected with PTTG cDNA Constructs

	Cell line	Growth in Soft Agar	Efficiency of Colony
			formation in Soft Agar (%)*
5	No DNA	0	0
	Vector only	1.3 \pm 0.7	0.013
	PTTG 3	26 \pm 4.6	0.26
	PTTG 4	132 \pm 26	1.32
	PTTG 8	33 \pm 6.0	0.33
10	PTTG 9	72 \pm 13	0.72
	PTTG 10	92 \pm 18	0.92

*Efficiency of colony formation was calculated as percentage of number of colonies divided by total number of cells.

15

The results indicate that NIH 3T3 parental cells and 3T3 cells transfected with pCMV vector do not form colonies on soft agar, whereas 3T3 cells transfected with *PTTG* form large colonies. In addition, focal transformation is observed in cells over-expressing PTTG protein, but cells expressing pCMV vector without the PTTG insert showed similar morphology to the parental 3T3 cells.

20

Example 8: Assay to determine whether PTTG is tumorigenic in vivo

To determine whether PTTG is tumorigenic in vivo, *PTTG*-transfected 3T3 cells were injected subcutaneously into athymic nude mice. 3×10^5 cells of either PTTG or pCMV vector-only transfected cells were resuspended in PBS and injected subcutaneously into nude mice (5 for each group). Tumors were excised from sacrificed animals at the end of the 3rd week and weighed. All injected animals developed large tumors (1-3 grams) within 3 weeks. The results are shown in Table 14 below. No mouse injected with vector-only transfected cells developed tumors. These results clearly indicate that *PTTG* is a potent transforming gene in vivo.

25

Table 14: In vivo Tumorigenesis by NIH 3T3 Cells Transfected with PTTG cDNA Expression Vector

30

<u>Cell line</u>	<u>No. Animals injected</u>	<u>Tumor formation</u>
------------------	-----------------------------	------------------------

Vector only	5	0/5
PTTG 4	5	5/5

5 Example 9: Human Carcinoma Cell Lines Express *PTTG*.

The pattern of expression of *PTTG* in various human cell lines was studied employing a multiple human cancer cell line Northern blot (Clontech). The specific cell lines tested are shown in Table 15 below.

10 Table 15. Human Carcinoma Cell Lines Tested

	Cell Line	<i>PTTG</i> Expression
	1 Promyelocytic Leukemia HL-60	+
	2 HeLa Cell S3	+
15	3 Chronic Myelogenous Leukemia K-562	+
	4 Lymphoblastic Leukemia MOLT-4	+
	5 Burkitt's lymphoma Raji	+
	6 Colorectal Adenocarcinoma SW 480	+
	7 Lung Carcinoma A549	+
20	8 Melanoma G361	+

About 2 µg polyA RNA from each of the 8 cell lines indicated in Table 3 above were placed on each lane of a denaturing formaldehyde 1.2% agarose gel, separated by denaturing gel electrophoresis to ensure intactness, transferred to a charge-modified nylon membrane by Northern blotting, and fixed by UV irradiation. Lanes 1 to 8 contained RNA from promyelocytic leukemia HL-60, HeLa cell line S3, human chronic myelogenous leukemia K-562, lymphoblastic leukemia MOLT-4, Burkitt's lymphoma Raji, colorectal adenocarcinoma SW 480, lung

carcinoma A549 and melanoma G361, respectively. RNA size marker lines at 9.5, 7.5, 4.4, 2.4, and 1.35 kb were indicated in ink on the left margin of the blot, and utilized as sizing standards, and a notch was cut out from the lower left hand corner of the membrane to provide orientation. Radiolabeled human β -actin cDNA was utilized as a control probe for matching of different
5 batches of polyA RNAs. A single control band at 2.0 kb in all lanes spotted is confirmatory.

The blots were probed with the full length rat *PTTG* cDNA probe (SEQ. ID No: 1; 974 bp) at 60°C for 1 hr. in ExpressHyb hybridization solution (Clontech) as described by Sambrook et al., the relevant section of which reference is incorporated herein by reference. See, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd. Ed, Cold Spring Harbor Laboratory Press,
10 Cold Spring Harbor, N.Y. (1989). The blots were then washed twice for 15 min at room temperature in 2xSSC, 0.05% SDS, and twice for 15 min at 50°C in 0.1% SSC, 0.1% SDS. A more detailed description of the remaining experimental procedures may be found in Pei & Melmed, the relevant section of which is incorporated herein by reference. (See, Pei & Melmed, Endocrinology 4: 433-441 [1997]).

15 All cells tested by the Northern blot analysis as described above evidenced expression of human *PTTG* (i.e., *PTTGI*), including lymphoma, leukemia, melanoma and lung carcinomas, among others.

Example 10: Molecular cloning of human PTTG cDNA

A human fetal liver cDNA library (Clontech, Palo Alto, CA) was screened as described
20 by Maniatis et al. (Maniatis et al, Molecular cloning, Cold Spring Harbor Press, 1989), using a radioactively labeled cDNA fragment of the entire rat *PTTG* coding region as a probe. The cDNA inserts from positive clones were subcloned into plasmid pBluescript-SK (Stratagene, La Jolla, CA), and subjected to sequence analysis using Sequenase kit (U.S. Biochemical Corp., Cleveland, OH).

25 A complete open reading frame containing 606 bp was found in the positive clones. The homology between the nucleotide sequences of the open reading frame and the coding region of rat *PTTG* is 85%. Amino acid sequence comparison between the translated product of this open reading frame and rat *PTTG* protein reveals 77% identity and 89% homology. The cDNAs obtained from these clones represents human homologies of rat *PTTG*. No other cDNA fragments

with higher homology were detected from the library.

Example 11: Tissue Distribution of Human *PTTG* mRNA

Total RNA was prepared using Trizol Reagent (Gibco-BRL, Gaithersburg, MD) from normal human pituitary glands (Zoion Research Inc. Worcester, MA) and fresh human pituitary tumors collected at surgery and frozen in liquid nitrogen. 20 mg total RNA were used for 1% agarose gel electrophoresis. RNA blots (Clontech, Palo Alto, CA) derived from normal adult and fetal tissues as well as from malignant tumor cell lines, were hybridized with radioactively labeled human cDNA fragment containing the complete coding region. The RNA isolated from each cell line was transferred onto a nylon membrane (Amersham, Arlington Heights, IL), and hybridized with radioactively labeled probe at 55°C overnight in 6xSSC, 2xDenhardt's solution, 0.25% SDS. The membranes were washed twice at room temperature for 15 minutes each, and then for 20 minutes at 60°C in 0.5xSSC, 0.1% SDS, and autoradiographed. The autoradiography was carried out using Kodak BIOMEX-MR film (Eastman Kodak, Rochester, NY) with an intensifying screen. The blots were stripped by washing for 20 minutes in distilled water at 95°C for subsequent probing.

The results from the Northern blot analysis indicated that *PTTG* is expressed in liver, but not in brain, lung, and kidney of human fetal tissue. In addition, *PTTG* is strongly expressed in testis, modestly expressed in thymus, and weakly expressed in colon and small intestine of normal human adult tissue. No expression was detected by Northern analysis in brain, heart, liver, lung, muscle, ovary, placenta, kidney, and pancreas.

The expression of *PTTG* in several human carcinoma cell lines was also analyzed by Northern blots. In every carcinoma cells examined, *PTTG* was found highly expressed. The human tumor cell lines tested are listed in Table 16 below.

Table 16. Tested Human Tumor Cell Lines

25	Promyelocytic leukemia HL-60
	Epitheloid carcinoma HeLa cell S3
	Chronic myelogenous leukemia K-562
	Lymphoblastic leukemia MOLT-4
30	Burkitt's lymphoma Raji

- 5 Colorectal adenocarcinoma SW 480
Lung carcinoma A549
Melanoma G361
Hepatocellular carcinoma Hep 3B
Thyroid carcinoma TC-1
Breast adenocarcinoma MCF-7
Osteogenic sarcoma U2 OS
Placenta choriocarcinoma JAR
Choriocarcinoma JEG-3
- 10
-

Example 12: Human *PTTG* expression in normal pituitary and pituitary tumors

RT-PCR was performed as follows. 5 mg total RNA were treated with 100 U RNase-free DNase I at room temperature for 15 minutes. DNase I was inactivated by incubation at 65° C for 15 minutes. The sample was then used for reverse transcription using oligo-dT primer and SuperScript II reverse transcriptase (Gibco-BRL, Gaithersburg, MD). After reverse transcription, the sample was subjected to PCR amplification with PCR SuperMix (Gibco-BRL, Gaithersburg, MD) using h*PTTG*-specific primers and human cyclophilin A-specific primers as an internal control.

Northern blot analysis indicated that the level of expression of *PTTG* is quite low in normal pituitary as well as in pituitary tumors. Therefore, comparative RT-PCR was used to study the expression of *PTTG* quantitatively in normal pituitary and pituitary tumors. The results of this study showed that in most of pituitary tumors tested, including non-functioning tumors, GH-secreting tumors, and prolactinomas, the expression level of *PTTG* was higher than that of normal pituitary.

25 Example 13: Stable Transfection of Human *PTTG* into NIH 3T3 Cells

The complete coding region of h*PTTG* cDNA was subcloned in reading frame into the mammalian expression vector pBK-CMV (Stratagene, La Jolla, CA), and transfected into NIH 3T3 fibroblast cells by Lipofectamine (Gibco-BRL, Gaithersburg, MD) according to manufacturer's protocol. 24 hours after transfection, the cells were serially diluted and grown in selection medium containing 1 mg/ml G418 for 2 weeks. Individual clones were isolated and maintained in selection medium. Total RNA was isolated from h*PTTG*-transfected cell lines as

well as from control cells in which blank vector pBK-CMV had been transfected. Northern blot was performed to confirm overexpression of *hPTTG* in transfected cell lines. These cell lines were used in subsequent cell proliferation assay as well as in vitro and in vivo transformation assay.

Example 14: Cell Proliferation Assay

5 A cell proliferation assay was performed using the CellTiter 96 non-radioactive cell proliferation assay kit (Promega Medicine, WI) according to the manufacturer's protocol. 5,000 cells were seeded in 96-well plates and incubated at 37°C for 24-72 hours. Eight wells were used for each clone in each assay. At each time point, 15 ml of dye solution was added to each well and the cells were incubated at 37°C for 4 hours. After incubation, 100 ml solubilization/stop
10 solution were added to each well, and the plates incubated overnight at room temperature. The absorbance was determined at 595 nm using an ELISA plate reader.

 Control and *hPTTG*-overexpressing NIH 3T3 cells were used to perform this assay. The results indicated that the growth of cells transfected with the *PTTG*-expressing vector was suppressed by 30~45% as compared with cells transfected with blank vector. These results clearly
15 show that the *PTTG* protein inhibits cell proliferation.

Example 15: In Vitro and In Vivo Transformation Assay

(a) In vitro transformation assay

 Control and *hPTTG*-transfected cells were tested for anchorage-independent growth in soft agar. 3 ml of soft agar (20% of 2X DMEM, 50% DMEM, 10% fetal bovine serum, and 20%
20 of 2.5% agar, melted and mixed at 45°C) were added to 35mm tissue dishes. 10,000 cells were mixed with 1 ml soft agar and added to each dish, and incubated for 2 weeks until colonies could be counted and photographed.

(b) In vivo transformation assay

5×10^5 cells containing either a blank vector or *hPTTG*-expressing cells were injected into
25 nude mice. The mice were sacrificed two weeks after injection, and the tumors formed near the

injection sites examined.

When the NIH 3T3 cells stably transfected with the *PTTG*-expressing vector were tested in an anchorage-independent growth assay, these cells caused large colony formation on soft agar, suggesting the transforming ability of PTTG protein.

- 5 When the NIH 3T3 cells were injected into nude mice, they caused in vivo tumor formation within 2 weeks after injection. These data indicate that human *PTTG*, as its rat homologue, is a potent transforming gene.

Example 16: Inhibition of Cell Transformation/Tumor formation by PTTG C-Terminal Polypeptide

- 10 Cell lines. NIH 3T3 cells were maintained in high glucose (4.5 g/L) DMEM (Gibco-BRL) supplemented with 10% fetal bovine serum. HeLa cells were maintained in low glucose (1 g/L) DMEM (Gibco-BRL) supplemented with 10% fetal bovine serum (FBS). T-47D and MCF-7 cells were maintained in high glucose DMEM (Gibco-BRL) supplemented with 10% fetal bovine serum and 0.01 mg/mL bovine insulin (Sigma). All cell lines were obtained from American Type
15 Culture Collection (ATCC).

- Site-directed mutagenesis and stable transfection of human and mutant *PTTG* into NIH 3T3 cells.
Point mutations on the proline-rich domain(s) of wild type human PTTG polypeptide (wtPTTG) were generated by PCR-based site-directed mutagenesis. Two synthetic oligonucleotides, 5'-GATGCTCTCCGCACTCTGGGAATCCAATCTG-3' (SEQ. ID. NO.:5) and 5'-
20 TTCACAAGTTGAGGGGCGCCCAGCTGAAACAG-3' (SEQ. ID. NO.:6), which cause point mutations that result in amino acid sequence changes P163A, S165Q, P166L, P170L, P172A, and P173L in the wtPTTG protein, were used to amplify human *PTTG* cDNA cloned into pBlue-Script-SK vector (Stratagene). Amplified mutated cDNA (mutPTTG) was then cloned into mammalian expression vector pCI-neo (Promega). Overexpression of mutPTTG in transfected
25 cells was confirmed by Northern analysis and RT-PCR followed by direct sequence analysis. wtPTTG and mutPTTG were subcloned into pCI-neo, and the vector was used to transfect NIH 3T3 cells as described in Zhang, X., *et al.* [1999a].

Transactivation assay. wtPTTG cDNA was fused in frame with pGAL4 (Stratagene), designated pGAL4-wtPTTG and was used as template for deletion and mutation analysis; mutPTTG cDNA was also fused in frame with pGAL4 and designated pGAL4-mutPTTG. pGAL4-VP16 was used as a positive control. Experimental plasmids; were co-transfected with pLUC and pCMV- β -Gal (as internal control). Cell lysates were prepared 48 hours after transfection and assayed for luciferase activity as described (Wang, Z. and Melmed, S. [2000]; Sambrook, J., *et al.*, *Molecular Cloning: A Laboratory Manual*, 2d Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 10.2.1-10.2.6[1989]).

Constructions of expression vectors for wild type and mutant human PTTG C-terminal polypeptides. To generate wtPTTG and mutPTTG C-terminal polypeptide expression vector, the internal *Xba* I site of wtPTTG and mutPTTG cDNA and the 3'-portions of these cDNAs were cloned into pCI-neo (Promega, Madison, WI) via *Xba* I and *Not* I sites. In these clone, the ATG for M147 of full-length PTTG is used as an initiation codon, generating a polypeptide of 56 amino acid residues corresponding to nucleotide positions 147 through 202 of full-length wtPTTG.

Stable transfection of human PTTG C-terminal peptide into tumor cells. Wild type and mutant PTTG C-terminal expression constructs were transfected into HeLa, MCF-7, and T47-D cells with Lipofectin (GIBCO-BRL) according to the manufacturer's protocol. Twenty-four hours after transfection, cells were serially diluted and selected with G418 (1 mg/mL) for 2 weeks. Individual clones were isolated and maintained in selection medium (respective high or low glucose DMEM with 10% FBS, as described above, and G148 [1 mg/mL]), and total RNA was extracted from transfected cells. Expression of wild-type and mutated PTTG -C terminal was confirmed by RT-PCR using two synthetic oligonucleotides, with one specific to the 5'-nontranslational region from vector pCI-neo, 5'-GGCTAGAGTACTTAATACGACTCACTATAGGC-3' (SEQ. ID. NO.:7), and the other to the 3'-translational region of PTTG1 cDNA, 5'-CTATGTCACAGCAAACAGGTGGCAATTCAAC-3' (SEQ. ID. NO.:8), followed by direct sequence analysis.

In vitro colony formation and in vivo tumorigenesis. NIH 3T3 stable transfectants were tested

in vivo as described in Zhang, X., *et al.* [1999a]. Transfected cells were tested for anchorage-independent growth in soft agar as described Zhang, X., *et al.* [1999a]. HeLa cells were incubated for 3 weeks and MCF-7 and T-47D cells for 2 weeks. For in vivo assays of tumorigenesis, 1×10^7 MCF-7 stable transfectants were resuspended in 500 μ L MATRIGEL basement membrane matrix (Becton Dickinson, Bedford, MA) and were injected subcutaneously into nude mice (three mice for each group). After four weeks, animals were photographed and tumors were excised and weighed.

ELISA of basic fibroblast growth factor (bFGF) in conditioned medium. The concentration of basic fibroblast growth factor (bFGF) concentration in HeLa cell culture medium was assayed using Quantikine HS Human FGF Basic Immunoassay Kit (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. Cells (1×10^5) were plated in 100-mm cell culture dishes. After 72 hours, the culture medium was collected and 200 mL was used for ELISA assay.

Effects of wild type human *PTTG* and mutant *PTTG* overexpression on tumor induction. It was previously demonstrated that NIH 3T3 cells overexpressing wild type PTTG formed large colonies in an anchorage-independent growth assay and formed tumors when injected into athymic nude mice, while point mutations in the proline-rich region (P163A, P170L, P172A, and P173L) abrogated formation of colonies and tumors (Zhang, X., *et al.* [1999a]). Overexpression of wtPTTG and mutPTTG (P163A, S165Q, P166L, P170L, P172A, and P173L) in each transfectant cell line was confirmed by Northern analysis and RT-PCR followed by direct sequence analysis (not shown).

It was further shown that overexpressing *PTTG* transfectants injected into athymic nude mice caused tumor formation within 2 weeks in all injected animals. Five mice in each of three groups were injected subcutaneously with 3×10^5 NIH 3T3 cells transfected with: (1) control cell line (transfected with pGAL4 vector alone); (2) wild type *PTTG*-overexpressing (wtPTTG); or (3) mutant PTTG-overexpressing (mutPTTG [P163A, S 165Q, P166L, P170L, P172A, and P173L]). After 2 weeks, mice were sacrificed and tumors were excised and weighed. In the mice injected with control transfectants or mutPTTG transfectants, no tumors developed. but mice injected with transfectant cells bearing wtPTTG developed tumors without exception.

Tumor weights ranged from 470 to 1500 mg (Table 17).

Table 17. Tumor formation by PTTG-expressing NIH 3T3 Cells in Athymic Nude Mice.

<u>Tumor weight (mg)</u>			
	<u>Vector</u>	<u>wtPTTG</u>	<u>mutPTTG</u>
5	none*	1500	none
	none	770	none
	none	1250	none
	none	550	none
	none	470	none

10 *none = no detectable tumor.

PTTG exhibits transcriptional activation. Vector pGal4 alone (negative control) did not activate the luciferase (*luc*) reporter, and a known activation domain, VP16, significantly increased reporter activity about 28-fold. pGAL4-wtPTTG exhibited transactivation properties and induced reporter activity about 22-fold (Figure 1).

15 Transcriptional activity of pGAL4-mutPTTG (mutated proline region [P163A, S165Q, P166L, P170L, P172A, and P173L]), other point mutations, as well as a separate deletions (d) of wtPTTG were also tested as indicated in Table 18. In Table 18, the indicated plasmids were co-transfected with pLuc and pCMV- β -Gal into NIH 3T3 cells, and luciferase assays were performed, with β -Gal serving as the internal control. Each value represents triplicate wells from
20 two independent experiments (\pm SEM); transactivation by wtPTTG was designated 100%. pGAL4-mutPTTG exhibited about 95% transactivating activity compared to pGAL4-wtPTTG, thus confirming the importance of the wtPTTG proline-rich motif for transactivation.

Table 18. Transactivation assay of hPTTG mutants.

	<u>Mutant</u>	<u>activation activity (%) (±SEM)</u>
	pGAL4-wtPTTG	100
	-163 Pro → Ala	100 ± 10
	-166 Pro → Ala	45 ± 5*
5	-170 Pro → Ala	100 ± 10
	-182 Pro → Ala	100 ± 10
	-152 Glu → Gln	100 ± 10
	-192 Glu → Gln	50 ± 3*
	-165 Ser → Ala	30 ± 3*
10	-165 Ser → Leu	20 ± 2*
	-176 Ser → Ala	100 ± 10
	-183 Ser → Ala	100 ± 10
	-184 Ser → Ala	100 ± 10
	-d(1-100)	100 ± 10
15	-d(180-202)	100 ± 10
	-mutPTTG	6 ± 1*

* p < 0.01

Human PTTG C-terminal peptide expression blocks cell transformation. The critical role of the proline-rich region in transactivation, transformation and tumor formation, as described above, implies that PTTG functions through SH3-mediated signal transduction. If human PTTG1 protein mediates the SH3-related signal cascade, it probably contains at least two functional domains interacting with upstream and downstream signal molecule(s), respectively. A mutant protein containing only one such functional domain could then act in a dominant-negative manner to abrogate wild-type protein function and disrupt signal transduction.

Based on this hypothesis, a truncated PTTG1 mutant peptide, lacking N-terminal amino acid residues 1- 146, was introduced into human carcinoma cells. An expression construct was used expressing a PTTG-C peptide corresponding to residues 147-202 of the full-length protein,

under the control of a CMV promoter. This polypeptide contains the proline-rich domain(s) (residues 163-173; Zhang, X., *et al.* [1999a]), and when the coding sequence was fused to glutathione S-transferase (GST), it was expressed in *Escherichia coli* as an intact protein with the appropriate molecular weight (data not shown). Mutant expression vector pCIneo-mutPTTG
5 (mutated proline region [P163A, S165Q, P166L, P170L, P172A, and P173L]), as well as the empty vector pCI-neo alone as control, were stably transfected into HeLa, MCF-7, and T-47D human carcinoma cell lines.

Transfectants expressing wild-type PTTG carboxy-terminal peptide (PTTG-C), PTTG C-terminal mutated in several proline residues (PTTG-Cpm; mutated proline region [P163A,
10 S165Q, P166L, P170L, P172A, and P173L]), and vector (V), were isolated. Expression of each transfectant line was confirmed by RT-PCR, using a primer directed to the 5'-nontranslational region of the expression vector and a primer directed to the 3'-translational region of *PTTG* mRNA, followed by direct sequence analysis (Figures 2A, 2B, and 2C). Transforming abilities of all three of these stably transfected cell lines were tested in an anchorage-independent growth
15 assay, PTTG-Cpm cells were observed to form large colonies, as did control V cells containing the same expression vector but lacking either wild type or mutant C-terminal polypeptide. Each transfectant cell line was plated in three different plates. HeLa was scored on the 21st day and T-47D and MCF-7 on the 14th day. Colonies consisting of 60 or more cells were scored. However, the number and size, of colonies formed by cells expressing PTTG-C were markedly
20 reduced ($p<0.01$) (Figure 3). Table 19 (below) summarizes the soft agar colony formation for each cancer cell type.

Table 19. Colony Formation by PTTG I C-terminal (PTTG-C) and mutant PTTG C-terminal (PTTG-Cpm) Expressing Cells in Soft Agar.

5	Cell Line	Vector	Colonies/ 10 ⁴ Cells
			(mean \pm SEM)
10	HeLa	Vector alone	1465 \pm 54
		Vector alone	2392 \pm 55
		PTTG-C	11 \pm 2*
		PTTG-C	6 \pm 1*
		PTTG-C	48 \pm 3*
		PTTG-C	3 \pm 1*
		PTTG-Cpm	1169 \pm 77
		PTTG-Cpm	1097 \pm 79
15	T-47D	PITG-Cpm	2615 \pm 76
		Vector alone	135 \pm 4
		PTTG-C	46 \pm 5*
		PTTG-C	52 \pm 2*
		PTTG-Cpm	193 \pm 5
20	MCF-7	PTTG-Cpm	106 \pm 5
		Vector alone	287 \pm 3
		PTTG-C	9 \pm 3*
		PTTG-C	34 \pm 4*
		PTTG-Cpm	236 \pm 11
25		PTTG-Cpm	206 \pm 4
		*P<0.01	

Human PTTG C-terminal polypeptide-expressing MCF-7 cells fail to develop tumors in vivo.
 Stably transfected MCF-7 cell lines were injected (1×10^7 cells/per mouse in 500 μ L MATRIGEL

basement membrane matrix) subcutaneously into athymic nude mice. After four weeks, mice were photographed, killed, and their tumors were excised and weighed. Three mice injected with cells transfected with control vector only developed visible tumors in 4 weeks, while three mice injected with PTTG-C-transfected cells failed to generate tumors. At autopsy, absence of

5 subcutaneous or other peripheral tumor formation was confirmed in the mice receiving PTTG-C transfected cells. Three mice injected with PTTG-Cpm-transfected cells also developed tumors after 4 weeks, which were similar in size to those developed in mice injected with control vector-transfected cells, indicating that the mutated PTTG-C-terminal polypeptide lost its ability to abrogate endogenous PTTG function (Table 20).

10 Table 20. Tumor formation by PTTG-C expressing MCF-7 Cells in Athymic Nude Mice.

<u>Tumor weight (mg)</u>		
<u>Vector</u>	<u>PTTG-C</u>	<u>PTTG-Cpm</u>
212	none*	185
235	none	196
15 209	none	203

*none = no detectable tumor.

These results show that overexpression of the PTTG C-terminal peptide caused cancer cells to lose their abilities for in vitro cell transformation and ex vivo tumor growth. Also, the importance of proline-rich regions is further confirmed here, since PTTG C-terminal peptide

20 containing point mutations of these proline residues failed to interfere with transforming activity or tumor-forming activity in vivo.

Suppression of bFGF secretion and PRL expression by PTTG-C peptide. As cells expressing wild-type human PTTG-C terminal peptide had markedly reduced colony forming ability on soft agar and were also unable to induce solid tumor growth in vivo, expression of bFGF was tested

25 in HeLa transfectants. An enzyme-linked immunoabsorbent assay (ELISA) was performed to examine bFGF levels in conditioned medium derived from 72-hour cultures of HeLa transfectants.

As shown in Figure 4, bFGF levels were markedly decreased in conditioned medium derived from PTTG-C DNA-transfected cells than those derived from vector-only and PTTG-Cpm-transfected cells, indicated a suppression of bFGF secretion resulting from the presence of PTTG carboxy-terminal peptide.

5 Since, the growth rate of solid tumors is directly related to activation of angiogenesis and recruitment of new blood vessels, this shows that, in accordance with the inventive method, the ability for new blood vessel growth can be impaired by the inventive PTTG-C peptides, providing an additional mechanism leading to the failure of *in vivo* neoplastic cellular proliferation and tumor growth. Experimental tumors do not grow more than 1 or 2 mm in diameter in the
10 absence of angiogenesis. (Folkman, J., N. Engl. J. Med. 285:1182-1186 [1971]; Folkman, J., and Klagsburn, M. (1987) Science 235:442-447 [1987]). The human cancer cell lines used in this study form prominent solid tumors (>2 mm in diameter) indicating active angiogenesis.

 Moreover, these results imply that additional hormonal regulatory cascades can be affected by the inventive PTTG-C peptides, because reduced bFGF secretion can result in altered
15 expression of bFGF-mediated pathways, for example prolactin (*PRL*) expression. For example, expression of the same human wild-type PTTG-C-terminal peptide (amino acid residues 147-202 of SEQ. ID. NO.:4) in rat prolactin (*PRL*)- and growth hormone (GH)-secreting GH3 cells caused markedly reduced *PRL* promoter activity (about 16-fold decrease), *PRL* mRNA expression (about 10-fold decrease), and prolactin protein expression (about 72-fold decrease)
20 in comparison to rat GH3 cells transfected with control vector alone or GH3 cells expressing a mutated PTTG1 C-terminal fragment (P163A, S165Q, P166L, P170A, P172A, and P173L; data not shown). Furthermore, a compensatory increase in GH mRNA (about 13-fold increase) and protein (about 37-fold increase) were observed in the PTTG-C-terminal expressing GH3 cells. These observations demonstrate that PTTG carboxy-terminal peptide expressed in GH3 cells
25 alters the hormonal secretory pattern by silencing *PRL*-gene expression and augmenting *GH* expression.

Example 17: Expression of PTTG in Normal and Leukemic T-Lymphocyte Cells

Cell culture. T-lymphocytes were prepared by positive selection of mononuclear cells from fresh peripheral venous blood of healthy human adults. In some experiments leukopack preparations of American Red Cross anonymous donors were used. Mononuclear blood cells were isolated by gradient centrifugation using Lymphoprep™ KIT (Nycomed Pharma AS, Oslo, Norway). When leukopack preparations were used, the isolated mononuclear cells were first frozen in 90% fetal bovine serum (FBS) supplemented with 10% DMSO. These cells were thawed and washed and grown in RPMI-1640 medium supplemented with 10% FBS. Human Jurkat leukemia T cell and human HL-60 promyelocytic leukemia cells were grown in the same medium.

Double T cell selection was performed using immunomagnetic beads (DynaL CD2™ CELlection™ KIT, Dynal AS, Oslo, Norway), and cells were further activated by culturing in Petri dishes containing immobilized anti-human monoclonal CD3 antibody (PharMingen International, Becton Dickinson Co.). Antibody immobilization was achieved by 90 min incubation (37°C) of fresh 60 mm plastic Petri dishes filled with 1 mL of anti-CD3 solution (10 µg/mL) in phosphate buffered saline (PBS). KIT protocols provided by the manufacturers were used during isolation and activation of T-cells. In some experiments, resting T-cells were activated using phytohemagglutinin (PHA, 5 µg/mL, Gibco-BRL). In each experiment, cells were labeled with triple fluorochrome-labeled anti-CD3/CD19/CD45 antibodies (Caltag Laboratories, Inc., Burlingame, CA) and then were studied using flow cytometry (Becton-Dickinson FACScan) in order to check relative amounts of anti-CD3-labeled T-lymphocytes in the cell population. Samples containing 95-97% of T cells and 0-0.05% of B cells were used in the experiments. Cells were also treated with sodium salt of hydrocortisone 21-hemisuccinate (0.1-1 µM, Sigma, St.Louis, MO), cyclosporin A (1 µg/mL, Calbiochem, SanDiego, CA), TGF beta1 (10 ng/mL, R & D Systems, Inc., Minneapolis, MN), aphidicolin (1 µg/mL, Calbiochem), nocodazole (500 ng/mL, Calbiochem) beginning from zero time after the starting of cell activation. Control experiments for dissolvants (0.1% C₂H₅OH (aphidicolin) and 0.2% DMSO (nocodazole)) did not evidence an effect on *PTTG* mRNA expression.

Northern blot analysis. Total RNA was isolated using TRIzol Reagent (Gibco-BRL, Grand Island, NY); RNA (about 5 µg for T cells and 20 µg for Jurkat cells) was electrophoresed

in 1% agarose-formaldehyde gel and blotted onto Hybond-N membranes (Amersham International, UK). The membranes were UV-cross-linked, prehybridized for 1 hour at 68°C in QuickHyb solution (Stratagen, La Jolla, CA), and then were hybridized for 3 hours at 68°C in the same solution supplemented with random-primed ³²P-labeled human *PTTG* cDNA (2 × 10⁶ cpm/mL) and sonicated and denaturated salmon sperm DNA (Stratagen). When IL-2 mRNA expression was studied, sequences of oligonucleotide sense and anti-sense primers for PCR preparation of IL-2 cDNA probe (sized 457 base pairs) were as previously reported. (Butch, AW *et al.*, *Cytokine expression by germinal center cells*, J Immunol. 150:39-47.[1993]). Cyclophilin cDNA probe was from Ambion, Inc. (Austin, TX). The membranes were washed twice (20 min each time) in 1xSSC and 0.1% SDS at room temperature, followed by one wash (30 min) in 0.2xSSC and 0.1% SDS at 60°C. After washing membrane was exposed to X-ray film (Kodak, Rochester, NY) overnight.

Western blot analysis. Cells were harvested in Eppendorf tubes and lysed for 15 min on ice in lysis buffer: 50 mM HEPES, 150 mM NaCl, 10 mM EDTA, 10 mM Na₄P₂O₇, 100 mM NaF, 2 mM sodium orthovanadate, pH 7.4, supplemented before use with 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 µg/mL aprotinin, 2 mM leupeptin. Protein concentration was determined in the lysed cells' supernatants, and aliquots containing 50 µg of protein were diluted in SDS-PAGE sample buffer, boiled for 5 min, cooled, centrifuged and separated in 10% SDS-PAGE. Proteins were transferred onto PVDF Immobilon-P membrane (Millipore, Bedford, MA). Membrane was incubated with polyclonal rabbit antiserum against human PTTG polypeptide fragment (1:3,000 dilution) at 4°C overnight, followed by incubation with peroxidase-linked secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Blots were visualized using ECL Western Blotting Detection Reagent (Amersham).

FACS analysis. To study cell cycle patterns cells were pelleted by centrifugation, washed in cold (4°C) phosphate-buffered saline (PBS), resuspended in 1 mL of PBS, and then 2 mL of cold methanol was slowly added for cell fixation.

500 µL of propidium iodide (500 µg/mL PBS) together with 1 µL of ribonuclease A (10 units/µL) were added and cell suspension was vortexed. After incubation for 1 hour at 4° C, cell

samples were analyzed by flow cytometry, performed on Becton-Dickinson FACScan. Analysis regions contained a minimum of 10,000 events. Cell cycle analysis was then performed on these data on Modfit software using Macintosh computer.

Cell labeling with triple mouse anti-CD3/CD19/CD45 flouochrome-labeled antibodies
5 was performed using manufacturer protocol (Caltag Laboratories, Inc., Burlingame, CA). Shortly
15 μ L of Caltag triple antibody was added to 100 μ L of cell suspension, and then 180 μ L of PBS
was added and gently mixed. Tubes were incubated at room temperature for 15 min in the dark,
cells were fixed using Cal-Lyse Lysing Solution (Caltag Laboratories, Inc.), washed with 3 mL
of deionized water, pelleted by centrifugation and resuspended in 1 mL of cold PBS. Flow
10 cytometry was done using a Becton-Dickinson FACScan.

All experiments were repeated at least 3 times, and the results of a typical experiment are
presented immediately below.

PTTG expression was upregulated upon T-cell activation. It is known that T-cell
activation needs a complex interaction between T lymphocyte and antigen-presenting cell.
15 (Crabtree GR, Clipstone NA, *Signal transmission between the plasma membrane and nucleus*
of T lymphocytes, Annu Rev Biochem. 63:1045-1083 [1994]). T cell receptor interaction with
major histocompatibility complex generates the most important signals for T-cell activation,
although some adhesive interactions as well as costimulatory molecules are also of great
significance here. T-cell surface molecules appear to provide costimulatory signals in two ways:
20 either quantitatively by augmenting the second messenger generated by TCR/CD3 complex (for
example, CD2), or qualitatively (for example, CD28) by generating intracellular biochemical signals
distinct from those generated by TCR/CD3 complex. The procedure which we used for positive
T-cell included T-cell binding to anti-CD2-coated immunomagnetic beads followed by cell
culturing in anti-CD3-coated dishes. Although immunomagnetic beads themselves were not able
25 to activate T-cells (no increase in *PTTG* mRNA expression and in cell cycling was observed) they
could serve as a co-stimulator for T-cells. As an indirect argument for this suggestion could be
our observation (data are not presented in this study) that T-cells isolated using cell sorter could
not be activated neither with immobilized anti-CD3-antibodies, nor with PHA.

After resting human T cells were treated with a T-cell mitogen CD3 antibody, T-cells

began to proliferate as shown by cells sequentially entering S phase and G2/M phase (Figure 5). *PTTG* mRNA expression was practically non-existent in resting T-cells but it was dramatically increased as percentage of cells in S and G2/M phase became substantial. After resting T-lymphocyte cells were stimulated with another mitogen (phytohemagglutinin [PHA]), a similar time course was seen for both T-cell proliferation and *PTTG* expression (data not shown). T-cell proliferation and *PTTG* expression after 3 days of PHA stimulation were similarly dependent on PHA concentration up to 5 µg/mL (Figure 6). Higher concentrations of PHA further increased S phase but decreased G2/M phase, but had no further effect on *PTTG* expression.

IL-2 is the most important early T cell activation gene. (Crabtree, G.R. and Clipstone, N.A., *Signal transmission between the plasma membrane and nucleus of T lymphocytes*, Annu Rev Biochem. 63:1045-1083 [1994]; Weiss A., *T lymphocyte activation*. In: Paul WE, ed. *Fundamental Immunology*. 3rd Edition. New York: Raven Press, Ltd. [1993] pp. 467-497; Kronke, M. et al., *Cyclosporine A inhibits T- cell growth factor gene expression at the level of mRNA transcription*, Proc Nat Acad Sci USA. 1984;81:5214-5218 [1984]).

In contrast to the expression of *PTTG*, which was upregulated at later time, interleukin 2 (IL-2) expression was increased early and before cell proliferation (Figure 7). IL-2 expression was first increased 6 hours after induction by immobilized anti-CD3 antibody application, long before any cells were in S or G2/M phase, suggesting this phase of IL-2 expression was independent of cell proliferation. At that time neither *PTTG* mRNA expression, nor significant amount of S-phase could be seen. Another phase of IL-2 elevated expression occurred 48 hours after the beginning of T cell activation, after T-cells had begun to proliferate. At that time considerable amount of *PTTG* mRNA and both S- and G2/M-phase cells were observed, which implies that IL-2 mRNA was already produced by proliferating T cells.

Cyclophilin, a house-keeping gene that also is an intracellular cyclosporin A-binding protein, was also increased as T-cells were activated by PHA (Figure 8). It is known that cyclophilins serve as intracellular cyclosporin A-binding proteins. (Crabtree GR and Clipstone NA, *Signal transmission between the plasma membrane and nucleus of T lymphocytes*. Annu Rev Biochem. 63:1045-1083 [1994]). Cyclophilins possess peptidyl prolyl-cis-trans isomerase activity involved in the catalysis of the cis-trans isomerization of proline residues in polypeptide substrates. This enzymatic activity may play some role in T-cell signal transduction cascade,

perhaps by catalyzing the correct folding of an inactive signaling intermediate into an active form. However, strong arguments exist that this simplified model is not the main mechanism of cyclosporin A action. It was shown that cyclosporin A-cyclophilin complex can block the action of calcineurin (calcium/calmodulin-regulated serine/threonine protein phosphatase) via regulating nuclei entry of transcription factor NF-AT (nuclear factor-activated T cells) which in its turn regulates T cell specific IL-2 gene expression. (Crabtree GR and Clipstone NA, Signal transmission between the plasma membrane and nucleus of T lymphocytes. *Annu Rev Biochem.* 63:1045-1083 [1994]). We found that the level of cyclophilin mRNA expression is significantly increasing after PHA-induced T cell activation, which implies that the activated T-cells should be more sensitive to the action of cyclosporin A than the resting T-cells because they have higher cyclophilin levels.

It is known that both IL-2 (Crabtree and Clipstone [1994]) and PTTG (Kakar SS, *Molecular cloning, genomic organization, and identification of the promoter for the human pituitary tumor transforming gene*, *Gene*. 240:317-324 [1999]) gene promoter contain AP-1 binding regions which suggests the existence of common regulators of expression of these two genes. It is also accepted that a known immunosuppressor cyclosporin A exerts its inhibitory action towards T lymphocytes via IL-2 gene suppression and this leads to the inhibition of DNA synthesis in T cells. (Crabtree and Clipstone [1994]; Kronke M *et al.*, *Cyclosporine A inhibits T- cell growth factor gene expression at the level of mRNA transcription*, *Proc Nat Acad Sci USA*. 81:5214-5218 [1984]).

Although glucocorticoids have different (from cyclosporin A) intracellular receptors, they were also shown to suppress IL-2 and interferon-gamma production and to favor the production of IL-4 in T cells. (Clerici M, Trabattoni D, Piconi S *et al.* *A possible role for the cortisol/anticortisols imbalance in the progression of human immune deficiency virus.* *Psychoneuroendocrinology*. 22 Suppl 1:S27-S31 [1997]). Another mechanism previously described for glucocorticoids' action is based on the induction of T cell apoptosis. (Cidlowski JA *et al.*, *The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system*, *Recent Prog Horm Res*. 51:457-490 [1996]). We found dose-dependent inhibition by hydrocortisone of both *PTTG* mRNA expression and the amount of S- and G2/M-phase T cells, although in low doses (final concentration 20 nM) this steroid hormone

slightly increased these indexes. Immunosuppressants hydrocortisone (Figure 9) and cyclosporin A (Figure 10) inhibited PHA-stimulated T cell proliferation and *PTTG* expression. The inhibitory effect of cyclosporin A was much stronger, while hydrocortisone action was even slightly stimulatory at low doses and was inhibitory at concentrations higher than 100 nM. These results further implied that *PTTG* expression is associated with T-cell proliferation. In general, even in the presence of very high hydrocortisone doses one can observe some *PTTG* expression and T cell cycling, while cyclosporin A suppresses T-cell functions in a much stronger manner. It should be also noted that hydrocortisone did not inhibit *PTTG* expression in Jurkat leukemia T cell line (see below).

PTTG expression in leukemic cells. Human leukemia cell lines HL-60 and Jurkat grow in 10%-FBS-supplemented RPMI-1640 medium without CD3 or PHA as shown by the presence of S phase cells (Figure 11). The abundance of *PTTG* mRNA in HL-60 and Jurkat cells was comparable to that in the activated T-cells by PHA or CD3 antibody. Among three immunomodulators used (cyclosporin A, hydrocortisone, and TGF- β 1), only cyclosporin A acted in similar way on *PTTG* mRNA expression and cell cycling in both normal T-cells and Jurkat T cells, while the effects of hydrocortisone and TGF- β 1 were specific for each of these two experimental models.

Cell cycle-dependent *PTTG* expression. We have shown that *PTTG* mRNA expression was cell-cycle dependent with peak expression at G2/M in a tumor cell line. We found a similar dependence of *PTTG* expression on cell cycle in T cells. This dependence was much more prominent in the case of normal T cells (Figure 12) than in the case of Jurkat T-cell leukemia line (Figure 13). Although the direction of revealed changes in the amount of S-phase cells and level of *PTTG* mRNA expression in normal T cells and Jurkat T cell line were mostly similar, the amplitude of these changes was found to be lower in the malignant Jurkat cells probably because of Jurkat cells' immortality and high basal levels of *PTTG*.

We found that CD3 antibody-induced activation of T-cells was inhibited to different extents by cyclosporin A, hydrocortisone, aphidicolin (S phase inhibitor), or nocodazole (G2/M phase blocker), while TGF- β 1 (10 ng/mL final concn) had no significant effect neither on *PTTG*

mRNA nor on the amount of S- or G2/M-phase cells (Figure 12). At the same time, neither fresh 1% or 10% FBS nor a mixture of phytohemagglutinin (PHA) and phorbol-12-myristate-13-acetate (PMA) [i.e., PHA+PMA mixture] considerably elevated *PTTG* level in Jurkat T-cell line and this mixture even decreased it. Jurkat cells were used for comparison and they were treated with PHA+PMA mixture which is used for its mitogenic action for Jurkat T cells after being cultured for 48 hours in 1% FBS-supplemented medium. Changes in the amount of S-phase cells were also parallel to changes in the level of *PTTG* mRNA expression. Cyclosporin A and TGF- β 1 decreased both *PTTG* mRNA level and the amount of S-phase Jurkat cells, while hydrocortisone did not change these indexes even used in 10 μ M final concentration (data are not shown).

It should be noted that TGF- β 1 is well known for its bi-directional action on cell functions including cell proliferation which strongly depends on the properties of cell targets and the conditions of their treatment. At the same time when Jurkat T cells were used we detected TGF- β 1-triggered inhibition of both *PTTG* mRNA expression and cell cycling. Although this effect was not observed in the presence of fresh FBS added to culture medium (data are not shown) and could be seen only after Jurkat cells' treatment with PHA+PMA mixture.

These results show that the expression of *PTTG* can be easily regulated in normal T-cells. It is induced to high level by both non-specific (PHA) and specific (anti-CD3 antibodies) T-cell activators, and this induction can be inhibited by known immunosuppressors - cyclosporin A and hydrocortisone. Importantly, preliminary data showed that the transfection of PHA-activated T cells with DNA encoding *PTTG* C-terminal region caused a decrease in the amount of S-phase cells and their accumulation in G2/M-phase of cell cycle.

Interestingly, hydrocortisone did not inhibit *PTTG* expression in Jurkat T cell line widely used for studying of T-cell functions, while another immunomodulator, TGF- β 1 did not affect *PTTG* expression in normal T-cells, but decreased it in Jurkat cells. Thus, the results of study of *PTTG* functioning in Jurkat T cell line cannot be directly applied for normal T-cells, probably because of high basic level of expression of *PTTG* oncogene in the malignant cells.

Normal T cells and Jurkat T-cell line also possessed different sensitivity to the action of cell cycle inhibitors (aphidicolin and nocodazole). Aphidicolin stopped Jurkat cells in S-phase, decreasing the amount of G2/M-phase, while no significant changes in *PTTG* mRNA level were observed (data not shown). Nocodazole stopped these cells in G2/M-phase and S-phase cells

were poorly detected in its presence, while some increase in *PTTG* mRNA expression was observed after nocodazole treatment of Jurkat cells. Probably, normal T-cells are more sensitive to the toxic effect of cell cycle inhibitors and in their presence both *PTTG* mRNA level and the amount of cycling cells were decreased.

- 5 The results presented herein show that targeting *PTTG* and PTTG expression is useful both for anti-neoplastic therapy and also for immunosuppressive therapy.

- While the present invention is not committed to or dependent any particular mechanism of action, *PTTG* mRNA induction and parallel S-phase increase during normal T-cell activation imply that the mechanism of *PTTG* cell transforming action could be in its overexpression and
10 resulting increase in cell cycling rather than in its misregulating effect on chromatide separation and resulting aneuploidy.

We claim:

1. A method of inhibiting the activation of a mammalian T-lymphocyte cell comprising:
inhibiting *PTTG* expression and/or endogenous *PTTG* function in the T-lymphocyte cell,
whereby activation of the T-lymphocyte cell is inhibited.
2. The method of Claim 1, further comprising delivering a *PTTG*-specific antisense oligonucleotide to the T-lymphocyte cell.
3. The method of Claim 1, further comprising interfering with SH3-mediated signal transduction by blocking specific binding to SH3-binding sites on endogenous *PTTG* protein molecules.
4. The method of Claim 1, further comprising:
delivering to the mammalian T-lymphocyte cell a composition comprising a *PTTG* carboxy-terminal-related polynucleotide, said polynucleotide being complexed with a cellular uptake-enhancing agent, in an amount and under conditions sufficient to allow the polynucleotide to enter the cell, whereby activation of the lymphocyte cell is inhibited.
5. The method of Claim 1, wherein the T-lymphocyte cell is of human origin.
6. The method of Claim 1, wherein the T-lymphocyte cell is cultured *in vitro*.
7. The method of Claim 4, further comprising administering the composition to a mammalian subject, such that the composition is delivered to the lymphocyte cell *in vivo*.
8. The method of Claim 4, wherein the polynucleotide is a DNA or DNA analog.
9. The method of Claim 4, wherein the polynucleotide is an antisense oligonucleotide.
10. The method of Claim 4, wherein the polynucleotide is a protein nucleic acid.
11. The method of Claim 8, wherein the composition further comprises an expression vector comprising a promoter, and the *PTTG* carboxy-terminal-related polynucleotide is operatively linked to the promoter in a transcriptional unit.

12. The method of Claim 11, wherein the polynucleotide encodes a PTTG carboxy-terminal peptide.

13. The method of Claim 12, wherein the polynucleotide defines a nucleotide base sequence encoding a mammalian PTTG-C peptide selected from the group consisting of

(A) peptides having an amino acid sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:16), or (SEQ. ID. NO.:17);

5 (B) mammalian PTTG-C peptides having at least about 60% sequence homology with any of (A); and

(C) peptide fragments of (A) or (B) that comprise at least 15 contiguous amino acid residues and that function to downregulate endogenous *PTTG* expression and/or PTTG function.

14. The method of Claim 13, wherein the peptide fragment of (C) comprises a proline-rich region.

15. The method of Claim 13, wherein the polynucleotide has a nucleotide sequence consisting of

(A) (SEQ. ID. NO.:10), (SEQ. ID. NO.:18), or (SEQ. ID. NO.:19)

(B) a degenerate coding sequence of any of (A);

5 (C) a sequence complementary to any of (A) or (B); or

(D) a polynucleotide fragment comprising at least 45 contiguous nucleotides of any of (A), (B) or (C).

16. The method of Claim 1, comprising:

delivering to the mammalian T-lymphocyte cell, a composition comprising an expression vector comprising a promoter and a polynucleotide, said polynucleotide comprising a first DNA segment encoding a mammalian PTTG-C peptide, said polynucleotide being operatively linked to the promoter in a transcriptional unit, said PTTG-C peptide being selected from the group consisting of

5 (A) peptides having an amino acid sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:16), or (SEQ. ID. NO.:17);

(B) mammalian PTTG-C peptides having at least about 60% sequence homology with any of (A); and

- 10 (C) peptide fragments of (A) or (B) that comprise at least 15 contiguous amino acid residues and that function to downregulate endogenous *PTTG* expression and/or *PTTG* function, said expression vector being complexed with a cellular uptake-enhancing agent, in an amount and under conditions sufficient to enter the lymphocyte cell, such that the *PTTG*-C peptide is expressed in the T- lymphocyte cell, whereby activation of the lymphocyte cell is inhibited.
17. The method of Claim 16, wherein the peptide fragment of (C) comprises a proline-rich region.
18. The method of Claim 16, wherein the polynucleotide further comprises a second DNA segment encoding an uptake-enhancing and/or importation-competent peptide segment.
19. The method of Claim 18, wherein the cellular uptake-enhancing and/or importation-competent polypeptide is a human immunodeficiency virus TAT-derived peptide segment or a signal peptide from Kaposi fibroblast growth factor.
20. The method of Claim 16, further comprising administering the composition to a mammalian subject in need of treatment, such that the expression vector is delivered to the lymphocyte cell in vivo.
21. The method of Claim 1, further comprising:
delivering to the mammalian T-lymphocyte cell a composition comprising a *PTTG* carboxy terminal peptide, or a biologically functional fragment thereof, complexed with a cellular uptake-enhancing agent, in an amount and under conditions sufficient to enter the T-lymphocyte cell whereby activation of the
- 5 T-lymphocyte cell is inhibited.
22. The method of Claim 21, wherein the lymphocyte cell is of human origin.
23. The method of Claim 21, wherein the composition is delivered to the lymphocyte cell in vitro.
24. The method of Claim 21, further comprising administering the composition to a mammalian subject, such that the polynucleotide is delivered to the lymphocyte cell in vivo.

25. The method of Claim 21, wherein said uptake-enhancing agent is a polycationic lipid agent.

26. The method of Claim 21, wherein said uptake enhancing agent comprises a cellular uptake-enhancing and/or importation-competent peptide segment.

27. The method of Claim 26, wherein the cellular uptake-enhancing and/or importation-competent peptide segment is a human immunodeficiency virus TAT-derived peptide segment or a signal peptide from Kaposi fibroblast growth factor.

28. The method of Claim 1, further comprising:
delivering to the human lymphocyte cell a composition comprising a PTTG-C peptide being selected from the group consisting of

5 (A) peptides having an amino acid sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:16), or (SEQ. ID. NO.:17);

(B) mammalian PTTG-C peptides having at least about 60% sequence homology with any of (A); and

(C) peptide fragments of (A) or (B) that comprise at least 15 contiguous amino acid residues and that function to downregulate endogenous *PTTG* expression and/or PTTG function,
10 said expression vector being complexed with a cellular uptake-enhancing agent, in an amount and under conditions sufficient to enter the lymphocyte cell, such that the PTTG-C peptide is expressed in the lymphocyte cell, whereby activation of the lymphocyte cell is inhibited.

29. The method of Claim 28, wherein the peptide fragment of (C) comprises a proline-rich region.

30. The method of Claim 28, wherein the composition is delivered to the cell in vitro.

31. The method of Claim 28, further comprising administering the composition to a human subject in need of treatment, such that the PTTG-C peptide is delivered to the lymphocyte cell in vivo.

32. The method of Claim 28, wherein said uptake enhancing agent comprises a polycationic

lipid.

33. The method of Claim 28, wherein said uptake enhancing agent comprises a cellular uptake-enhancing and/or importation-competent peptide segment.

34. The method of Claim 33, wherein the cellular uptake-enhancing and/or importation-competent peptide segment is a human immunodeficiency virus TAT-derived peptide segment or a signal peptide from Kaposi fibroblast growth factor.

35. An in vitro method for screening substances for new immunosuppressive agents, comprising:

culturing mammalian T-lymphocytes;
exposing the cultured T-lymphocytes to a potential immunosuppressive agent in the presence of a known lymphocyte activator; and
detecting a change in the expression level of PTTG in the T-lymphocytes compared to control lymphocytes not exposed to the potential immunosuppressive agent, downregulation of PTTG expression being indicative of an immunosuppressive capacity possessed by the potential immunosuppressive agent.

36. A composition for inhibiting the activation of a mammalian T-lymphocyte, comprising a tamed HIV vector operatively linked to a PTTG carboxy-terminal-related polynucleotide.

37. The composition of Claim 36, wherein the polynucleotide encodes a mammalian PTTG-C peptide selected from the group consisting of

(A) peptides having an amino acid sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:16), or (SEQ. ID. NO.:17);

(B) mammalian PTTG-C peptides having at least about 60% sequence homology with any of (A); and

(C) peptide fragments of (A) or (B) that comprise at least 15 contiguous amino acid residues and that function to downregulate endogenous *PTTG* expression and/or PTTG function, encoding a PTTG carboxy-terminal peptide and a

38. The composition of Claim 36, further comprising a pharmaceutically acceptable carrier.

39. The composition of Claim 37, wherein said PTTG carboxy-terminal peptide is selected from the group consisting of

(A) peptides having an amino acid sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:16), or (SEQ. ID. NO.:17);

(B) mammalian PTTG-C peptides having at least about 60% sequence homology with any of (A); and

(C) peptide fragments of (A) or (B) that comprise at least 15 contiguous amino acid residues and that function to downregulate endogenous *PTTG* expression and/or PTTG function.

40. The composition of Claim 36, wherein the polynucleotide is a DNA or DNA analog.

41. The composition of Claim 36, wherein the polynucleotide is an antisense oligonucleotide.

42. The composition of Claim 36, wherein the polynucleotide is a protein nucleic acid.

43. The composition of Claim 36, wherein the polynucleotide encodes a mammalian PTTG-C peptide or a complementary sequence.

44. The composition of Claim 43, wherein the polynucleotide defines a nucleotide base sequence encoding a mammalian PTTG-C peptide selected from the group consisting of

(A) peptides having an amino acid sequence of (SEQ. ID. NO.:9), (SEQ. ID. NO.:16), or (SEQ. ID. NO.:17);

5 (B) mammalian PTTG-C peptides having at least about 60% sequence homology with any of (A); and

(C) peptide fragments of (A) or (B) that comprise at least 15 contiguous amino acid residues and that function to downregulate endogenous *PTTG* expression and/or PTTG function.

45. The composition of Claim 44, wherein the peptide fragment of (C) comprises a proline-rich region.

46. The composition of Claim 44, wherein the polynucleotide has a nucleotide sequence consisting essentially of

- (A) (SEQ. ID. NO.:10), (SEQ. ID. NO.:18), or (SEQ. ID. NO.:19)
(B) a degenerate coding sequence of any of (A);
5 (C) a sequence complementary to any of (A) or (B); or
(D) a polynucleotide fragment comprising at least 45 contiguous nucleotides of any of (A), (B)
or (C).

47. The composition of Claim 36, further comprising an expression vector comprising the polynucleotide in a transcriptional unit.

48. A kit for the treatment of neoplastic cellular proliferation of T-lymphocytes, said kit comprising:
the composition of Claim 36; and
instructions for the use of said composition for inhibiting neoplastic cellular proliferation and/or transformation of T-lymphocytes.

49. A kit for immunosuppressive therapy, said kit comprising:
the composition of Claim 36; and
instructions for the use of said composition for inhibiting the activation of T-lymphocytes.

50. A kit for the treatment of neoplastic cellular proliferation of T-lymphocytes, said kit comprising:
the composition of Claim 37; and
instructions for the use of said composition for inhibiting neoplastic cellular proliferation and/or transformation of T-lymphocytes.

51. A kit for immunosuppressive therapy, said kit comprising:
the composition of Claim 37; and
instructions for the use of said composition for inhibiting the activation of T-lymphocytes.

52. The method of Claim 2, wherein the antisense oligonucleotide specifically binds to a regulatory region in the *PTTG* promoter selected from the group consisting of SSCA, 8182, a cyclic-AMP responsive element, an estrogen responsive element, an insulin response element, SP1, and a GC Box.

53. An in vitro method for screening substances for new immunoenhancing agents that enhance the activation of mammalian T-lymphocytes, comprising:
- culturing the T-lymphocytes;
 - exposing the cultured T-lymphocytes to a potential immunoenhancing agent; and
- 5 detecting a change in the expression level of *PTTG* in the lymphocytes compared to control T-lymphocytes not exposed to the potential immunoenhancing agent, upregulation of *PTTG* expression being indicative of an immunoenhancing capacity possessed by the potential immunoenhancing agent.

ABSTRACT OF THE DISCLOSURES

Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation
10 of mammalian T-lymphocyte cells, including cells of human origin, in vitro or in vivo. Also
disclosed are methods of immunomodulating, i.e., inhibiting or inducing, the activation of T-
lymphocytes by modulating *PTTG* expression and/or PTTG protein function. In vitro methods
for screening substances for new immunosuppressing or immunoenhancing agents that modulate
the activation of mammalian T-lymphocytes are disclosed. Also disclosed are useful compositions
15 and kits.




Figure 1




Figure 2A




Figure 2B




Figure 2C

Vector

PTTG-C

PTTG-Cpm

HeLa

T47-D

MCF-7




Figure 3






Figure 4



pttg →



28S →



18S →

Figure 5






Figure 6



IL-2



28S →

18S →




Figure 7





Figure 8







Figure 9



pttg →




28S →



18S →

Figure 10



pttg →



28S →



18S →

Figure 11




Figure 12





Figure 13

Docket No.
CEDAR-44649

Declaration For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**MODULATING ACTIVATION OF LYMPHOCYTES AND SCREENING POTENTIAL
IMMUNOMODULATING AGENTS BY TARGETING PITUITARY TUMOR TRANSFORMING GENE
(PTTG) EXPRESSION AND/OR FUNCTION**

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International
Application Number _____
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

<u>PCT/US97/21463</u>	<u>PCT</u>	<u>11/21/1997</u>	<input checked="" type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional

60/031,338

(Application Serial No.)

11/21/1996

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, CFR Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

09/569,956

(Application Serial No.)

05/12/2000

(Filing Date)

Pending

(Status)
(patented, pending, abandoned)

08/894,251

(Application Serial No.)

07/23/1999

(Filing Date)

Pending

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Rostyslav Stoika	
Sole or first inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of second inventor, if any Gregory A. Horwitz	
Second inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of third inventor, if any Xun Zhang	
Third inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Full name of fourth inventor, if any Shlomo Melmed	
Fourth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	